

A serological assay to detect SARS-CoV-2 seroconversion

Nature Medicine

26, 1033-1036

DOI: [10.1038/s41591-020-0913-5](https://doi.org/10.1038/s41591-020-0913-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Are Lessons Learned in Setting Cut Points for Detection of Anti-Drug Antibodies Also Useful in Serology Assays for Robust Detection of SARS-CoV-2 Reactive Antibodies?. AAPS Journal, 2020, 22, 127.	2.2	3
2	The Rapid Coronavirus Antibody Test: Can We Improve Accuracy?. Frontiers in Medicine, 2020, 7, 569.	1.2	12
3	Persistence of Anti-SARS-CoV-2 Antibodies in Non-Hospitalized COVID-19 Convalescent Health Care Workers. Journal of Clinical Medicine, 2020, 9, 3188.	1.0	68
4	Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity, 2020, 53, 925-933.e4.	6.6	301
5	Impact of primary culture: A true positive culture rate mystery. Transfusion, 2020, 60, 2459-2460.	0.8	0
6	Antibody Profiling of COVID-19 Patients in an Urban Low-Incidence Region in Northern Germany. Frontiers in Public Health, 2020, 8, 570543.	1.3	16
7	Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip. Biosensors and Bioelectronics, 2020, 169, 112578.	5.3	207
8	Biosensor and molecular-based methods for the detection of human coronaviruses: A review. Molecular and Cellular Probes, 2020, 54, 101662.	0.9	40
9	Diagnosis of COVID-19: facts and challenges. New Microbes and New Infections, 2020, 38, 100761.	0.8	13
10	Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19. Cell Reports Medicine, 2020, 1, 100078.	3.3	160
11	Magnetic-Nanosensor-Based Virus and Pathogen Detection Strategies before and during COVID-19. ACS Applied Nano Materials, 2020, 3, 9560-9580.	2.4	81
12	Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nature Protocols, 2020, 15, 3699-3715.	5.5	291
13	Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation. Biosensors and Bioelectronics, 2020, 169, 112572.	5.3	52
14	S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit. MBio, 2020, 11, .	1.8	188
15	Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell, 2020, 183, 982-995.e14.	13.5	440
16	Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26382-26388.	3.3	340
17	Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. Cell Reports Medicine, 2020, 1, 100126.	3.3	200
18	Accurate Diagnosis of COVID-19 by a Novel Immunogenic Secreted SARS-CoV-2 orf8 Protein. MBio, 2020, 11, .	1.8	61

#	ARTICLE	IF	CITATIONS
19	Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. <i>European Journal of Immunology</i> , 2020, 50, 2025-2040.	1.6	188
20	“America First” Will Destroy U.S. Science. <i>Cell</i> , 2020, 183, 841-844.	13.5	1
21	Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. <i>PLoS ONE</i> , 2020, 15, e0241104.	1.1	158
22	In Utero Vertical Transmission of Coronavirus Disease 2019 in a Severely Ill 29-week Preterm Infant. <i>AJP Reports</i> , 2020, 10, e270-e274.	0.4	9
24	Review of chest CT manifestations of COVID-19 infection. <i>European Journal of Radiology Open</i> , 2020, 7, 100239.	0.7	47
25	Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh. <i>International Journal of Infectious Diseases</i> , 2020, 101, 220-225.	1.5	55
26	Sex differences in immune responses that underlie COVID-19 disease outcomes. <i>Nature</i> , 2020, 588, 315-320.	13.7	1,035
27	Benefits and limitations of serological assays in COVID-19 infection. <i>Indian Journal of Tuberculosis</i> , 2020, 67, S163-S166.	0.3	64
28	Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. <i>Science Immunology</i> , 2020, 5, .	5.6	714
29	Early diagnosis and population prevention of coronavirus disease 2019. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 345-350.	1.5	2
30	Non-synonymous mutations of SARS-CoV-2 leads epitope loss and segregates its variants. <i>Microbes and Infection</i> , 2020, 22, 598-607.	1.0	40
31	A serological aptamer-assisted proximity ligation assay for COVID-19 diagnosis and seeking neutralizing aptamers. <i>Chemical Science</i> , 2020, 11, 12157-12164.	3.7	84
32	Point-of-Care Biosensor-Based Diagnosis of COVID-19 Holds Promise to Combat Current and Future Pandemics. <i>ACS Applied Bio Materials</i> , 2020, 3, 7326-7343.	2.3	123
33	SARS-CoV-2 vaccines in development. <i>Nature</i> , 2020, 586, 516-527.	13.7	1,659
34	Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. <i>Lancet Microbe</i> , The, 2020, 1, e283-e289.	3.4	133
35	Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patients. <i>Biosensors and Bioelectronics</i> , 2020, 169, 112643.	5.3	30
36	Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. <i>Cell</i> , 2020, 183, 143-157.e13.	13.5	599
37	Canadian society of clinical chemists (CSCC) interim consensus guidance for testing and reporting of SARS-CoV-2 serology. <i>Clinical Biochemistry</i> , 2020, 86, 1-7.	0.8	17

#	ARTICLE	IF	CITATIONS
38	Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. <i>Cell Reports Medicine</i> , 2020, 1, 100099.	3.3	61
39	Cross-reactive memory T cells and herd immunity to SARS-CoV-2. <i>Nature Reviews Immunology</i> , 2020, 20, 709-713.	10.6	229
40	SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients. <i>Scientific Reports</i> , 2020, 10, 16561.	1.6	84
41	Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. <i>Frontiers in Public Health</i> , 2020, 8, 384.	1.3	13
42	Review of Viral Testing (Polymerase Chain Reaction) and Antibody/Serology Testing for Severe Acute Respiratory Syndrome-Coronavirus-2 for the Intensivist. , 2020, 2, e0154.		22
43	SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. <i>Nature Communications</i> , 2020, 11, 3581.	5.8	251
44	Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature Medicine</i> , 2020, 26, 1428-1434.	15.2	400
45	Comprehensive mapping of immune perturbations associated with severe COVID-19. <i>Science Immunology</i> , 2020, 5, .	5.6	677
46	Evaluation of Six Commercial Mid- to High-Volume Antibody and Six Point-of-Care Lateral Flow Assays for Detection of SARS-CoV-2 Antibodies. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	90
47	Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges. <i>Life Sciences</i> , 2020, 257, 118058.	2.0	11
48	Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape. <i>Biosensors and Bioelectronics</i> , 2020, 165, 112454.	5.3	323
49	A serological assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood spots. <i>Scientific Reports</i> , 2020, 10, 20188.	1.6	58
50	Newborn Dried Blood Spots for Serologic Surveys of COVID-19. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e454-e456.	1.1	17
51	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. <i>EBioMedicine</i> , 2020, 62, 103132.	2.7	77
52	SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. <i>Immunity</i> , 2020, 53, 1281-1295.e5.	6.6	285
53	A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2. <i>Molecules</i> , 2020, 25, 5392.	1.7	26
54	Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia, USA, 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2974-2978.	2.0	41
55	Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19. <i>Scientific Reports</i> , 2020, 10, 20533.	1.6	66

#	ARTICLE	IF	CITATIONS
56	Microfluidic devices for the detection of viruses: aspects of emergency fabrication during the COVID-19 pandemic and other outbreaks. <i>Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences</i> , 2020, 476, 20200398.	1.0	34
57	Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity. <i>Frontiers in Medicine</i> , 2020, 7, 592629.	1.2	54
58	Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2. <i>Annals of Internal Medicine</i> , 2020, 173, 450-460.	2.0	124
59	Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy. <i>Tumori</i> , 2021, 107, 446-451.	0.6	126
60	SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors. <i>Immunity</i> , 2020, 53, 1245-1257.e5.	6.6	194
61	Is Vertical Transmission of SARS-CoV-2 Infection Possible in Preterm Triplet Pregnancy? A Case Series. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e456-e458.	1.1	6
62	Convalescent Plasma - Is it Useful for Treating SARS Co-V2 infection?. <i>Indian Journal of Medical Microbiology</i> , 2020, 38, 252-260.	0.3	7
63	Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic. <i>Frontiers in Pediatrics</i> , 2020, 8, 605807.	0.9	34
64	Assessment of serological techniques for screening patients for COVID-19 (COVID-SER): a prospective, multicentric study. <i>BMJ Open</i> , 2020, 10, e041268.	0.8	19
65	Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation. <i>EClinicalMedicine</i> , 2020, 29-30, 100651.	3.2	126
66	SARS-CoV-2 Transmission among Marine Recruits during Quarantine. <i>New England Journal of Medicine</i> , 2020, 383, 2407-2416.	13.9	94
67	Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases. <i>Microorganisms</i> , 2020, 8, 1733.	1.6	16
68	Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands. <i>Nature Communications</i> , 2020, 11, 5744.	5.8	80
69	Multi-species ELISA for the detection of antibodies against SARS-CoV-2 in animals. <i>Transboundary and Emerging Diseases</i> , 2021, 68, 1779-1785.	1.3	66
70	Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	137
71	Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2. <i>Clinics in Laboratory Medicine</i> , 2020, 40, 603-614.	0.7	12
72	SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. <i>Journal of Infectious Diseases</i> , 2020, 222, 1452-1461.	1.9	116
73	Beyond serosurveys: Human biology and the measurement of SARS-CoV-2 antibodies. <i>American Journal of Human Biology</i> , 2020, 32, e23483.	0.8	11

#	ARTICLE	IF	CITATIONS
74	Low Incidence and Mortality from SARS-CoV-2 in Southern Europe. Proposal of a hypothesis for Arthropod borne Herd immunity. <i>Medical Hypotheses</i> , 2020, 143, 110121.	0.8	2
75	Comprehensive Analyses of SARS-CoV-2 Transmission in a Public Health Virology Laboratory. <i>Viruses</i> , 2020, 12, 854.	1.5	21
76	Point-of-Use Rapid Detection of SARS-CoV-2: Nanotechnology-Enabled Solutions for the COVID-19 Pandemic. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5126.	1.8	105
77	A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. <i>Nature Biotechnology</i> , 2020, 38, 1073-1078.	9.4	1,042
78	Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. <i>EBioMedicine</i> , 2020, 58, 102911.	2.7	120
79	Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1557.e1-1557.e7.	2.8	124
80	Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. <i>Npj Vaccines</i> , 2020, 5, 69.	2.9	121
81	A thermostable, closed SARS-CoV-2 spike protein trimer. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 934-941.	3.6	261
82	Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. <i>EBioMedicine</i> , 2020, 59, 102915.	2.7	101
83	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. <i>Immunity</i> , 2020, 53, 724-732.e7.	6.6	267
84	Unexpected diagnosis of COVID-19-associated disorders by SARS-CoV-2-specific serology. <i>Journal of Clinical Virology</i> , 2020, 132, 104568.	1.6	7
85	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , 2020, 584, 437-442.	13.7	1,742
86	Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. <i>Science</i> , 2020, 369, 1261-1265.	6.0	520
87	Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. <i>Science</i> , 2020, 370, 89-94.	6.0	1,036
88	Point-of-Care Diagnostics of COVID-19: From Current Work to Future Perspectives. <i>Sensors</i> , 2020, 20, 4289.	2.1	67
89	SARS-CoV-2 seroprevalence among parturient women in Philadelphia. <i>Science Immunology</i> , 2020, 5, .	5.6	121
90	Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. <i>Nature Communications</i> , 2020, 11, 3774.	5.8	78
91	Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies. <i>Vaccines</i> , 2020, 8, 443.	2.1	16

#	ARTICLE	IF	CITATIONS
92	SARS-CoV-2-specific ELISA development. <i>Journal of Immunological Methods</i> , 2020, 484-485, 112832.	0.6	77
93	Convalescent Plasma Therapy for COVID-19: State of the Art. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	5.7	94
94	Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression. <i>Physiology</i> , 2020, 35, 288-301.	1.6	164
95	A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. <i>Nature Communications</i> , 2020, 11, 4059.	5.8	266
96	<sc>Antiâ€SARSâ€CoV</sc>â€2 spike antibodies are stable in convalescent plasma when stored at 4Â° Celsius for at least 6â€weeks. <i>Transfusion</i> , 2020, 60, 2457-2459.	0.8	17
97	Kinetics and isotype assessment of antibodies targeting the spike protein receptorâ€binding domain of severe acute respiratory syndromeâ€coronavirusâ€2 in COVIDâ€19 patients as a function of age, biological sex and disease severity. <i>Clinical and Translational Immunology</i> , 2020, 9, e1189.	1.7	38
98	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. <i>Nature Microbiology</i> , 2020, 5, 1598-1607.	5.9	1,115
99	Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World. <i>Journal of Clinical Medicine</i> , 2020, 9, 3372.	1.0	54
100	Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics using immuno-informatics and structure-based drug discovery techniques. <i>Biomedicine and Pharmacotherapy</i> , 2020, 132, 110914.	2.5	24
101	Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	357
102	Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. <i>Science</i> , 2020, 370, 1227-1230.	6.0	1,035
103	Roadmap to the Bioanalytical Testing of COVID-19: From Sample Collection to Disease Surveillance. <i>ACS Sensors</i> , 2020, 5, 3328-3345.	4.0	37
104	Detection of SARS-CoV-2 Antibodies in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2753-2756.	3.0	34
105	Sensitivity and specificity of SARS-CoV-2 S1 subunit in COVID-19 serology assays. <i>Cell Discovery</i> , 2020, 6, 75.	3.1	27
106	Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates. <i>Nature Biomedical Engineering</i> , 2020, 4, 1188-1196.	11.6	77
107	Kidney transplantation using lymphocyte depleting induction and standard maintenance immunosuppression at the height of the SARSâ€CoVâ€2 pandemic in New York City: A singleâ€center experience. <i>Clinical Transplantation</i> , 2020, 34, e14055.	0.8	11
108	COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. <i>Journal of Clinical Microbiology</i> , 2020, 59, .	1.8	193
109	A High-Throughput Assay for Circulating Antibodies Directed Against the S Protein of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of Infectious Diseases</i> , 2020, 222, 1629-1634.	1.9	27

#	ARTICLE	IF	CITATIONS
110	Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	494
111	Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak. <i>Nature Communications</i> , 2020, 11, 4378.	5.8	63
112	Detection of the SARS-CoV-2 humanized antibody with paper-based ELISA. <i>Analyst, The</i> , 2020, 145, 7680-7686.	1.7	62
113	Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 180.	7.1	222
114	Are we underestimating seroprevalence of SARS-CoV-2?. <i>BMJ, The</i> , 2020, 370, m3364.	3.0	56
115	Nanotechnology Responses to COVID-19. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000979.	3.9	128
116	Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28693.	0.8	37
117	Potential Diagnostic Systems for Coronavirus Detection: a Critical Review. <i>Biological Procedures Online</i> , 2020, 22, 21.	1.4	13
118	Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). <i>Pediatrics</i> , 2020, 146, .	1.0	113
119	Antibody Responses to SARS-CoV-2: Let's Stick to Known Knowns. <i>Journal of Immunology</i> , 2020, 205, 2342-2350.	0.4	69
120	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 1390-1400.	4.6	336
121	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. <i>PLoS Pathogens</i> , 2020, 16, e1008817.	2.1	105
122	Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19. <i>Nature Biomedical Engineering</i> , 2020, 4, 1180-1187.	11.6	110
123	Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 25018-25025.	3.3	279
124	No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic. <i>Journal of Infectious Diseases</i> , 2020, 222, 1960-1964.	1.9	45
125	COVID-19 Infection Among Healthcare Workers: Serological Findings Supporting Routine Testing. <i>Frontiers in Medicine</i> , 2020, 7, 471.	1.2	35
126	Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. <i>Science</i> , 2020, 370, 725-730.	6.0	348
127	Sensitive and Specific Detection of SARS-CoV-2 Antibodies Using a High-Throughput, Fully Automated Liquid-Handling Robotic System. <i>SLAS Technology</i> , 2020, 25, 545-552.	1.0	22

#	ARTICLE	IF	CITATIONS
128	Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity. <i>Emerging Infectious Diseases</i> , 2020, 26, 1978-1986.	2.0	71
129	Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. <i>Nature Biotechnology</i> , 2020, 38, 1174-1183.	9.4	251
130	Immune responses during COVID-19 infection. <i>Oncolmmunology</i> , 2020, 9, 1807836.	2.1	103
131	Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. <i>Nature Medicine</i> , 2020, 26, 1708-1713.	15.2	405
132	Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. <i>Viruses</i> , 2020, 12, 1011.	1.5	54
133	Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: Experience at large transplant center in New York City. <i>Clinical Transplantation</i> , 2020, 34, e14089.	0.8	28
134	Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. <i>MSphere</i> , 2020, 5, .	1.3	62
135	Evaluation of Orthogonal Testing Algorithm for Detection of SARS-CoV-2 IgG Antibodies. <i>Clinical Chemistry</i> , 2020, 66, 1531-1537.	1.5	18
136	Rapid Response to Pandemic Threats: Immunogenic Epitope Detection of Pandemic Pathogens for Diagnostics and Vaccine Development Using Peptide Microarrays. <i>Journal of Proteome Research</i> , 2020, 19, 4339-4354.	1.8	23
137	Ultra-Sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease. <i>Clinical Chemistry</i> , 2020, 66, 1562-1572.	1.5	134
138	A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. <i>PLoS Pathogens</i> , 2020, 16, e1008796.	2.1	90
139	Suboptimal SARS-CoV-2-specific CD8 ⁺ T cell response associated with the prominent HLA-A*02:01 phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24384-24391.	3.3	168
140	High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay. <i>PLoS ONE</i> , 2020, 15, e0237833.	1.1	83
141	Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses. <i>Clinical Infectious Diseases</i> , 2021, 73, e2444-e2449.	2.9	137
142	Plasma From Recovered COVID-19 Patients Inhibits Spike Protein Binding to ACE2 in a Microsphere-Based Inhibition Assay. <i>Journal of Infectious Diseases</i> , 2020, 222, 1965-1973.	1.9	13
143	A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	228
144	Estimating unobserved SARS-CoV-2 infections in the United States. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22597-22602.	3.3	71
145	COVID-19 diagnostic testing: Technology perspective. <i>Clinical and Translational Medicine</i> , 2020, 10, e158.	1.7	61

#	ARTICLE	IF	CITATIONS
146	Analytical and Clinical Evaluation of the Automated Elecsys Anti-SARS-CoV-2 Antibody Assay on the Roche cobas e602 Analyzer. <i>American Journal of Clinical Pathology</i> , 2020, 154, 620-626.	0.4	26
147	Humoral Responses and Serological Assays in SARS-CoV-2 Infections. <i>Frontiers in Immunology</i> , 2020, 11, 610688.	2.2	190
148	Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures. <i>Frontiers in Medicine</i> , 2020, 7, 603996.	1.2	9
149	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). <i>Frontiers in Immunology</i> , 2020, 11, 571481.	2.2	48
150	Plant Molecular Farming as a Strategy Against COVID-19 – The Italian Perspective. <i>Frontiers in Plant Science</i> , 2020, 11, 609910.	1.7	15
151	Corona Pandemic: Assisted Isolation and Care to Protect Vulnerable Populations May Allow Us to Shorten the Universal Lock-Down and Gradually Re-open Society. <i>Frontiers in Public Health</i> , 2020, 8, 562901.	1.3	2
152	Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry. <i>Scientific Reports</i> , 2020, 10, 21738.	1.6	49
153	Pilot Production of SARS-CoV-2 Related Proteins in Plants: A Proof of Concept for Rapid Repurposing of Indoor Farms Into Biomanufacturing Facilities. <i>Frontiers in Plant Science</i> , 2020, 11, 612781.	1.7	47
154	Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials. <i>Vaccines</i> , 2020, 8, 746.	2.1	6
155	Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors. <i>Frontiers in Microbiology</i> , 2020, 11, 596851.	1.5	7
156	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2020, 8, 771.	2.1	61
157	Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies. <i>Current Protocols in Immunology</i> , 2020, 131, e116.	3.6	111
158	Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. <i>Blood Advances</i> , 2020, 4, 6051-6063.	2.5	105
159	Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2. <i>Pathogens</i> , 2020, 9, 1027.	1.2	20
160	Assessment of Seroconversion to SARS-CoV-2 in a Cohort of Pediatric Kidney Transplant Recipients. <i>Frontiers in Pediatrics</i> , 2020, 8, 601327.	0.9	6
161	Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. <i>Cell</i> , 2020, 183, 1901-1912.e9.	13.5	618
162	Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome—An Observational Pilot Study. <i>Frontiers in Immunology</i> , 2020, 11, 581338.	2.2	75
163	Intensive diagnostic management of coronavirus disease 2019 (COVID-19) in academic settings in Japan: challenge and future. <i>Inflammation and Regeneration</i> , 2020, 40, 38.	1.5	3

#	ARTICLE	IF	CITATIONS
164	SARS-CoV-2 Cysteine-like Protease Antibodies Can Be Detected in Serum and Saliva of COVID-19 Seropositive Individuals. <i>Journal of Immunology</i> , 2020, 205, 3130-3140.	0.4	32
165	Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. <i>Cell</i> , 2020, 183, 1508-1519.e12.	13.5	263
166	Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. <i>Viruses</i> , 2020, 12, 513.	1.5	641
167	Lessons From COVID-19 in Children: Key Hypotheses to Guide Preventative and Therapeutic Strategies. <i>Clinical Infectious Diseases</i> , 2020, 71, 2006-2013.	2.9	33
168	Immunology of COVID-19: Current State of the Science. <i>Immunity</i> , 2020, 52, 910-941.	6.6	1,387
169	Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115094.	0.8	293
170	The COVID-19 MS Coalition "accelerating diagnostics, prognostics, and treatment. <i>Lancet, The</i> , 2020, 395, 1761-1762.	6.3	51
171	Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1256.e9-1256.e11.	2.8	101
172	On the evolutionary epidemiology of SARS-CoV-2. <i>Current Biology</i> , 2020, 30, R849-R857.	1.8	160
173	Serological differentiation between COVID-19 and SARS infections. <i>Emerging Microbes and Infections</i> , 2020, 9, 1497-1505.	3.0	89
174	The end of social confinement and COVID-19 re-emergence risk. <i>Nature Human Behaviour</i> , 2020, 4, 746-755.	6.2	197
175	Prevalence of SARS-CoV-2 Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City. <i>Journal of General Internal Medicine</i> , 2020, 35, 2485-2486.	1.3	68
176	Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients. <i>Clinical Infectious Diseases</i> , 2020, 71, 2688-2694.	2.9	268
177	In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19. <i>Modern Pathology</i> , 2020, 33, 2104-2114.	2.9	257
179	The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. <i>Science Immunology</i> , 2020, 5, .	5.6	772
180	Out of the Darkness, Into the Light: Value of SARS-CoV-2 Antibody Testing in Populations to Benefit Public Health and in Individuals for Peace of Mind. <i>journal of applied laboratory medicine, The</i> , 2020, 5, 1101-1106.	0.6	0
181	The COVID-19 Serology Studies Workshop: Recommendations and Challenges. <i>Immunity</i> , 2020, 53, 1-5.	6.6	71
182	Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates. <i>Vaccine</i> , 2020, 38, 5653-5658.	1.7	49

#	ARTICLE	IF	CITATIONS
183	COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds. <i>Journal of Virology</i> , 2020, 94, .	1.5	79
184	Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization. <i>ELife</i> , 2020, 9, .	2.8	80
185	Antibody tests for identification of current and past infection with SARS-CoV-2. <i>The Cochrane Library</i> , 2020, 2020, CD013652.	1.5	664
186	Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests. <i>Journal of Clinical Virology</i> , 2020, 129, 104544.	1.6	73
187	Convalescent plasma therapy in patients with COVID-19. <i>Journal of Clinical Apheresis</i> , 2020, 35, 367-373.	0.7	29
188	A review on histotechnology practices in COVID-19 pathology investigations. <i>Journal of Histotechnology</i> , 2020, 43, 153-158.	0.2	2
189	Adaptive immunity to SARS-CoV-2. <i>Oxford Open Immunology</i> , 2020, 1, iqaa003.	1.2	10
190	Proteomics and Informatics for Understanding Phases and Identifying Biomarkers in COVID-19 Disease. <i>Journal of Proteome Research</i> , 2020, 19, 4219-4232.	1.8	63
191	LIPS method for the detection of SARS-CoV-2 antibodies to spike and nucleocapsid proteins. <i>European Journal of Immunology</i> , 2020, 50, 1234-1236.	1.6	30
192	Review of Current Advances in Serologic Testing for COVID-19. <i>American Journal of Clinical Pathology</i> , 2020, 154, 293-304.	0.4	131
193	An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. <i>Current Protocols in Microbiology</i> , 2020, 58, e108.	6.5	165
194	A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. <i>Cell Host and Microbe</i> , 2020, 28, 486-496.e6.	5.1	178
195	Using Serology with Models to Clarify the Trajectory of the SARS-CoV-2 Emerging Outbreak. <i>Trends in Immunology</i> , 2020, 41, 849-851.	2.9	7
196	The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: A systematic review. <i>International Journal of Infectious Diseases</i> , 2020, 98, 372-380.	1.5	88
197	Detecting the Coronavirus (COVID-19). <i>ACS Sensors</i> , 2020, 5, 2283-2296.	4.0	196
198	Response of ophthalmologists in Israel to the novel coronavirus (2019-nCoV) outbreak. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 1419-1426.	1.0	5
199	Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID-19. <i>Bioengineering and Translational Medicine</i> , 2020, 5, e10163.	3.9	7
200	The Role of Antibody Testing for SARS-CoV-2: Is There One?. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	282

#	ARTICLE	IF	CITATIONS
201	The serostatus approach to fighting COVID-19. <i>International Journal of Infectious Diseases</i> , 2020, 94, 53-54.	1.5	3
202	ISIDOG Recommendations Concerning COVID-19 and Pregnancy. <i>Diagnostics</i> , 2020, 10, 243.	1.3	71
203	The important role of serology for COVID-19 control. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 758-759.	4.6	201
204	SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. <i>Cell</i> , 2020, 181, 1016-1035.e19.	13.5	1,956
205	COVID-19 pandemicâ€”a focused review for clinicians. <i>Clinical Microbiology and Infection</i> , 2020, 26, 842-847.	2.8	289
206	Seroconversion in household members of COVID-19 outpatients. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 168.	4.6	11
207	Guidance for the procurement of COVIDâ€”19 convalescent plasma: differences between highâ€”and lowâ€”income countries. <i>Vox Sanguinis</i> , 2021, 116, 18-35.	0.7	48
208	Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 1501-1522.	2.4	95
209	Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for Patients With COVID-19â€”Nashville, Tennessee. <i>Clinical Infectious Diseases</i> , 2021, 72, 1645-1648.	2.9	104
210	Multisystem inflammatory syndrome in children related to COVIDâ€”19: A New York City experience. <i>Journal of Medical Virology</i> , 2021, 93, 424-433.	2.5	135
211	Development and clinical application of a rapid SARSâ€”CoVâ€”2 antibody test strip: A multiâ€”center assessment across China. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23619.	0.9	10
212	Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. <i>Nature Immunology</i> , 2021, 22, 25-31.	7.0	403
213	Longitudinal Echocardiographic Assessment of Coronary Arteries and Left Ventricular Function following Multisystem Inflammatory Syndrome in Children. <i>Journal of Pediatrics</i> , 2021, 228, 290-293.e1.	0.9	37
214	Dupilumab, severe asthma airway responses, and SARSâ€”CoVâ€”2 serology. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 957-958.	2.7	26
215	Magnitude and Kinetics of Antiâ€”Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity. <i>Clinical Infectious Diseases</i> , 2021, 72, 301-308.	2.9	175
216	Multiplexed detection and quantification of human antibody response to COVID-19 infection using a plasmon enhanced biosensor platform. <i>Biosensors and Bioelectronics</i> , 2021, 171, 112679.	5.3	89
217	Differences in Performance Characteristics Among Four High-Throughput Assays for the Detection of Antibodies Against SARS-CoV-2 Using a Common Set of Patient Samples. <i>American Journal of Clinical Pathology</i> , 2021, 155, 267-279.	0.4	37
218	COVID-19: Discovery, diagnostics and drug development. <i>Journal of Hepatology</i> , 2021, 74, 168-184.	1.8	302

#	ARTICLE	IF	CITATIONS
219	Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 490-493.e2.	2.0	72
220	A critical review of point-of-care diagnostic technologies to combat viral pandemics. <i>Analytica Chimica Acta</i> , 2021, 1146, 184-199.	2.6	44
221	A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. <i>Journal of Infectious Diseases</i> , 2021, 223, 10-14.	1.9	21
222	Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. <i>Nature Microbiology</i> , 2021, 6, 51-58.	5.9	113
223	Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 223, 197-205.	1.9	216
224	Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12998.	1.3	201
225	Highly Sensitive and Specific Multiplex Antibody Assays To Quantify Immunoglobulins M, A, and G against SARS-CoV-2 Antigens. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	64
226	Clinical performance evaluation of a SARS-CoV-2 Rapid Antibody Test for determining past exposure to SARS-CoV-2. <i>International Journal of Infectious Diseases</i> , 2021, 103, 636-641.	1.5	11
227	Comparison of SARS-CoV-2 serological tests with different antigen targets. <i>Journal of Clinical Virology</i> , 2021, 134, 104690.	1.6	65
228	Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. <i>Cell</i> , 2021, 184, 169-183.e17.	13.5	580
229	SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 589-599.	1.9	31
230	Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay. <i>Journal of Virological Methods</i> , 2021, 288, 114025.	1.0	94
231	Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19). <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 669-673.	0.6	45
232	SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up. <i>Journal of Infectious Diseases</i> , 2021, 223, 62-71.	1.9	55
233	Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. <i>Science</i> , 2021, 371, 79-82.	6.0	247
234	Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 864-868.	0.6	21
235	A high-throughput multiplexed microfluidic device for COVID-19 serology assays. <i>Lab on A Chip</i> , 2021, 21, 93-104.	3.1	53
236	A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. <i>Med</i> , 2021, 2, 149-163.e4.	2.2	85

#	ARTICLE	IF	CITATIONS
237	Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	102
238	Nanozyme chemiluminescence paper test for rapid and sensitive detection of SARS-CoV-2 antigen. <i>Biosensors and Bioelectronics</i> , 2021, 173, 112817.	5.3	195
239	The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition. <i>Journal of Molecular Biology</i> , 2021, 433, 166748.	2.0	12
240	Emerging biosensing technologies for improved diagnostics of COVID-19 and future pandemics. <i>Talanta</i> , 2021, 225, 121986.	2.9	43
241	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	379
242	Single-step, wash-free digital immunoassay for rapid quantitative analysis of serological antibody against SARS-CoV-2 by photonic resonator absorption microscopy. <i>Talanta</i> , 2021, 225, 122004.	2.9	43
243	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
244	Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. <i>Nature</i> , 2021, 590, 146-150.	13.7	128
245	The potential application of electrochemical biosensors in the COVID-19 pandemic: A perspective on the rapid diagnostics of SARS-CoV-2. <i>Biosensors and Bioelectronics</i> , 2021, 176, 112905.	5.3	109
246	Development of a high-throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. <i>Annals of Clinical Biochemistry</i> , 2021, 58, 123-131.	0.8	31
247	Technical considerations to development of serological tests for SARS-CoV-2. <i>Talanta</i> , 2021, 224, 121883.	2.9	27
248	Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages. <i>Talanta</i> , 2021, 225, 121898.	2.9	43
249	Molecular epidemiology in the HIV and SARS-CoV-2 pandemics. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 11-24.	1.5	5
250	Unexpected high frequency of unspecific reactivities by testing pre-epidemic blood specimens from Europe and Africa with SARS-CoV-2 IgG/IgM antibody rapid tests points to IgM as the Achilles heel. <i>Journal of Medical Virology</i> , 2021, 93, 2196-2203.	2.5	12
251	The scientific and ethical feasibility of immunity passports. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e58-e63.	4.6	82
252	Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 223, 56-61.	1.9	65
253	Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2. <i>Transfusion</i> , 2021, 61, 78-93.	0.8	17
254	Neutralizing Antibody Responses in COVID-19 Convalescent Sera. <i>Journal of Infectious Diseases</i> , 2021, 223, 47-55.	1.9	70

#	ARTICLE	IF	CITATIONS
255	Evaluation of the Truview Easy Check COVID-19 IgM/IgG Lateral Flow Device for Rapid Anti-SARS-CoV-2 Antibody Detection. <i>American Journal of Clinical Pathology</i> , 2021, 155, 286-295.	0.4	11
256	Production of trimeric SARS-CoV-2 spike protein by CHO cells for serological COVID-19 testing. <i>Biotechnology and Bioengineering</i> , 2021, 118, 1013-1021.	1.7	33
257	Infection with SARS-CoV-2 in primary care health care workers assessed by antibody testing. <i>Family Practice</i> , 2021, 38, 76-79.	0.8	25
258	A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization. <i>Infection</i> , 2021, 49, 75-82.	2.3	118
259	Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 261-268.	1.3	12
260	N-terminally truncated nucleocapsid protein of SARS-CoV-2 as a better serological marker than whole nucleocapsid protein in evaluating the immunogenicity of inactivated SARS-CoV-2. <i>Journal of Medical Virology</i> , 2021, 93, 1732-1738.	2.5	12
261	Antibody Responses and Clinical Outcomes in Adults Hospitalized With Severe Coronavirus Disease 2019 (COVID-19): A Post hoc Analysis of LOTUS China Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, e545-e551.	2.9	34
262	Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?. <i>Clinical Infectious Diseases</i> , 2021, 72, 1467-1474.	2.9	185
263	Use of convalescent plasma for COVID-19 in India: A review & practical guidelines. <i>Indian Journal of Medical Research</i> , 2021, 153, 64.	0.4	5
264	Study Protocol for DeCOMPRESS: Defining the Disease Course and Immune Profile of COVID-19 in the Immunosuppressed Patient. <i>HRB Open Research</i> , 0, 4, 6.	0.3	0
265	Vaccines™ Safety and Effectiveness in the Midst of Covid-19 Mutations. <i>Health</i> , 2021, 13, 283-298.	0.1	1
266	Prevalence of asymptomatic SARS-CoV-2 infection in elective surgical patients in Australia: a prospective surveillance study. <i>ANZ Journal of Surgery</i> , 2021, 91, 27-32.	0.3	8
267	Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals. <i>Frontiers in Microbiology</i> , 2020, 11, 618097.	1.5	30
268	ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population. <i>Vox Sanguinis</i> , 2021, 116, 766-773.	0.7	22
270	Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein. <i>Virology Journal</i> , 2021, 18, 16.	1.4	57
272	Influence of patient characteristics and immunosuppressant management on mortality in kidney transplant recipients hospitalized with coronavirus disease 2019 (COVID-19). <i>Clinical Transplantation</i> , 2021, 35, e14221.	0.8	21
273	Magnetic Bead-Based Immunoassay Allows Rapid, Inexpensive, and Quantitative Detection of Human SARS-CoV-2 Antibodies. <i>ACS Sensors</i> , 2021, 6, 703-708.	4.0	61
274	Decline in neutralising antibody responses, but sustained T-cell immunity, in COVID-19 patients at 7 months post-infection. <i>Clinical and Translational Immunology</i> , 2021, 10, e1319.	1.7	34

#	ARTICLE	IF	CITATIONS
275	Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort. <i>Emerging Microbes and Infections</i> , 2021, 10, 774-781.	3.0	38
276	Differential serological and neutralizing antibody dynamics after an infection by a single SARS-CoV-2 strain. <i>Infection</i> , 2021, 49, 781-783.	2.3	6
277	Capillary electrophoresis of glycoproteins. , 2021, , 645-727.		1
278	Epidemiology of COVID-19 in Misrata, Libya: A Population-Based Surveillance Study. <i>Open Journal of Epidemiology</i> , 2021, 11, 101-112.	0.2	2
279	Quantitative Measurement of IgG to Severe Acute Respiratory Syndrome Coronavirus-2 Proteins Using ImmunoCAP. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 417-424.	0.9	13
282	A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. <i>Cellular and Molecular Immunology</i> , 2021, 18, 318-327.	4.8	270
283	SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike. <i>MBio</i> , 2021, 12, .	1.8	81
284	COVID-19 myocarditis and postinfection Bellâ€™s palsy. <i>BMJ Case Reports</i> , 2021, 14, e240095.	0.2	23
285	Quasispecies of SARS-CoV-2 revealed by single nucleotide polymorphisms (SNPs) analysis. <i>Virulence</i> , 2021, 12, 1209-1226.	1.8	16
286	Charting elimination in the pandemic: a SARS-CoV-2 serosurvey of blood donors in New Zealand. <i>Epidemiology and Infection</i> , 2021, 149, e173.	1.0	8
288	An overview of current COVID-19 vaccine platforms. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2508-2517.	1.9	99
289	Persistence of SARS-CoV-2â€™Specific IgG in Children 6 Months After Infection, Australia. <i>Emerging Infectious Diseases</i> , 2021, 27, 2233-2235.	2.0	13
290	A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. <i>ACS Central Science</i> , 2021, 7, 183-199.	5.3	134
291	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021, 591, 639-644.	13.7	1,355
292	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants. <i>Glycobiology</i> , 2022, 32, 60-72.	1.3	16
293	Antibodies to neutralising epitopes synergistically block the interaction of the receptorâ€™binding domain of SARSâ€™CoVâ€™2 to ACE 2. <i>Clinical and Translational Immunology</i> , 2021, 10, e1260.	1.7	13
294	Antibody response to SARSâ€™CoVâ€™2 in infected patients with different clinical outcome. <i>Journal of Medical Virology</i> , 2021, 93, 2548-2552.	2.5	12
295	Serological assays and host antibody detection in coronavirus-related disease diagnosis. <i>Archives of Virology</i> , 2021, 166, 715-731.	0.9	15

#	ARTICLE	IF	CITATIONS
296	A 10-Minute "Mix and Read" Antibody Assay for SARS-CoV-2. <i>Viruses</i> , 2021, 13, 143.	1.5	16
297	Vision-Based Human Detection Techniques: A Descriptive Review. <i>IEEE Access</i> , 2021, 9, 42724-42761.	2.6	12
298	A comprehensive review on current COVID-19 detection methods: From lab care to point of care diagnosis. <i>Sensors International</i> , 2021, 2, 100119.	4.9	41
299	Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individuals. <i>Analyst</i> , The, 2021, 146, 4905-4917.	1.7	28
300	Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. <i>Emerging Microbes and Infections</i> , 2021, 10, 664-676.	3.0	69
301	Long-Term Analysis of Antibodies Elicited by Sputnik V in Tucuman, Argentina. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
302	Jobs, Housing, and Mask Wearing: Cross-Sectional Study of Risk Factors for COVID-19. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e24320.	1.2	20
303	Optimized Recombinant Production of Secreted Proteins Using Human Embryonic Kidney (HEK293) Cells Grown in Suspension. <i>Bio-protocol</i> , 2021, 11, e3998.	0.2	14
304	A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. <i>Nature Communications</i> , 2021, 12, 542.	5.8	200
305	Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. <i>PLoS Pathogens</i> , 2021, 17, e1009161.	2.1	62
307	Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features. <i>Clinical and Translational Immunology</i> , 2021, 10, e1258.	1.7	28
308	'One Year Later' - SARS-CoV-2-Specific Immunity in Mild Cases of COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
309	High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacajã (Kayapã) indigenous population in the Brazilian Amazon. <i>International Journal for Equity in Health</i> , 2021, 20, 50.	1.5	20
311	Immune dysregulation and system pathology in COVID-19. <i>Virulence</i> , 2021, 12, 918-936.	1.8	74
312	Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. <i>Cell Reports Medicine</i> , 2021, 2, 100189.	3.3	149
315	Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 2363.	0.3	5
317	Seroconversion and Abundance of IgG Antibodies against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean Population. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	0.9	3
318	Humoral immunological kinetics of severe acute respiratory syndrome coronavirus 2 infection and diagnostic performance of serological assays for coronavirus disease 2019: an analysis of global reports. <i>International Health</i> , 2022, 14, 18-52.	0.8	11

#	ARTICLE	IF	CITATIONS
319	Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 90.	0.4	6
320	The use of dried blood spots for the serological evaluation of SARS-CoV-2 antibodies. <i>Journal of Public Health</i> , 2022, 44, e260-e263.	1.0	18
321	Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19. <i>Cell Reports Medicine</i> , 2021, 2, 100193.	3.3	37
322	Prevalence of SARS-CoV-2 Infection in Children by Antibody Detection in Saliva: Protocol for a Prospective Longitudinal Study (Coro-Buddy). <i>JMIR Research Protocols</i> , 2021, 10, e27739.	0.5	1
323	Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. <i>Cancer Cell</i> , 2021, 39, 257-275.e6.	7.7	93
324	Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. <i>Science</i> , 2021, 371, .	6.0	2,268
326	COVID-19 antibody screening with SARS-CoV-2 red cell kodeocytes using routine serologic diagnostic platforms. <i>Transfusion</i> , 2021, 61, 1171-1180.	0.8	13
328	Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library. <i>Protein Science</i> , 2021, 30, 716-727.	3.1	16
329	Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1063-1071.	1.3	50
330	COVID-19 Antibody Tests and Their Limitations. <i>ACS Sensors</i> , 2021, 6, 593-612.	4.0	150
331	Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. <i>Nature Communications</i> , 2021, 12, 1260.	5.8	115
332	Comparison of diagnostic accuracy for eight SARS-CoV-2 serological assays. <i>Biochemia Medica</i> , 2021, 31, 121-133.	1.2	9
333	Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. <i>Nature Communications</i> , 2021, 12, 1152.	5.8	71
334	COVID-19 illness and autoimmune diseases: recent insights. <i>Inflammation Research</i> , 2021, 70, 407-428.	1.6	13
336	Establishment of Monoclonal Antibody Standards for Quantitative Serological Diagnosis of SARS-CoV-2 in Low-Incidence Settings. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab061.	0.4	8
341	High-level expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the EE1A1-based plasmid vector. <i>PLoS ONE</i> , 2021, 16, e0242890.	1.1	24
342	Quantifying asymptomatic infection and transmission of COVID-19 in New York City using observed cases, serology, and testing capacity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	196
343	Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19. <i>Clinical Microbiology Newsletter</i> , 2021, 43, 23-32.	0.4	29

#	ARTICLE	IF	CITATIONS
344	Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. <i>PLoS Pathogens</i> , 2021, 17, e1009165.	2.1	40
345	Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. <i>Nature Communications</i> , 2021, 12, 1162.	5.8	316
346	COVID-19 immune signatures reveal stable antiviral T _H cell function despite declining humoral responses. <i>Immunity</i> , 2021, 54, 340-354.e6.	6.6	177
347	COVID-19 vaccine candidates: A review. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2021, 75, 58-63.	0.1	1
348	Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins. <i>PLoS Pathogens</i> , 2021, 17, e1009282.	2.1	42
350	A serological assay to detect human SARS-CoV-2 antibodies. <i>Journal of Taibah University Medical Sciences</i> , 2021, 16, 57-62.	0.5	12
351	COVID-19 mRNA vaccines. <i>Journal of Genetics and Genomics</i> , 2021, 48, 107-114.	1.7	59
352	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021, 592, 616-622.	13.7	1,232
355	Serological Test to Determine Exposure to SARS-CoV-2: ELISA Based on the Receptor-Binding Domain of the Spike Protein (S-RBDN318-V510) Expressed in <i>Escherichia coli</i> . <i>Diagnostics</i> , 2021, 11, 271.	1.3	17
356	SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population. <i>Cell Reports Medicine</i> , 2021, 2, 100191.	3.3	32
359	Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. <i>EClinicalMedicine</i> , 2021, 32, 100734.	3.2	134
360	Discrete SARS-CoV-2 antibody titers track with functional humoral stability. <i>Nature Communications</i> , 2021, 12, 1018.	5.8	82
361	COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. <i>Vaccines</i> , 2021, 9, 171.	2.1	43
365	In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19. <i>Scientific Reports</i> , 2021, 11, 4290.	1.6	22
366	Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera. <i>MBio</i> , 2021, 12, .	1.8	64
367	Optical Detection of CoV-SARS-2 Viral Proteins to Sub-Picomolar Concentrations. <i>ACS Omega</i> , 2021, 6, 6404-6413.	1.6	38
368	Adaptive immunity to SARS-CoV-2 and COVID-19. <i>Cell</i> , 2021, 184, 861-880.	13.5	1,364
369	SARS-CoV-2 virus: Vaccines in development. <i>Fundamental Research</i> , 2021, 1, 131-138.	1.6	12

#	ARTICLE	IF	CITATIONS
372	SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 629185.	2.2	42
373	Diagnostic Value of IgM and IgG Detection in COVID-19 Diagnosis by the Mobile Laboratory B-LiFE: A Massive Testing Strategy in the Piedmont Region. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3372.	1.2	3
374	The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A. <i>Blood Advances</i> , 2021, 5, 1305-1309.	2.5	83
376	<i>Lactiplantibacillus plantarum</i> as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines. <i>Microorganisms</i> , 2021, 9, 683.	1.6	25
377	What do we know about the antibody responses to SARS-CoV-2?. <i>Immunobiology</i> , 2021, 226, 152054.	0.8	23
378	A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies. <i>Nature Communications</i> , 2021, 12, 1806.	5.8	36
381	Multiplex bead binding assays using off-the-shelf components and common flow cytometers. <i>Journal of Immunological Methods</i> , 2021, 490, 112952.	0.6	10
382	Most Japanese individuals are genetically predisposed to recognize an immunogenic protein fragment shared between COVID-19 and common cold coronaviruses. <i>F1000Research</i> , 2021, 10, 196.	0.8	7
383	Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2. <i>Biology</i> , 2021, 10, 208.	1.3	16
386	Ultrasensitive Measurement of Both SARS-CoV-2 RNA and Antibodies from Saliva. <i>Analytical Chemistry</i> , 2021, 93, 5365-5370.	3.2	34
387	COVID-19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors. <i>Transfusion</i> , 2021, 61, 1471-1478.	0.8	9
389	Real-time measurement of the uncertain epidemiological appearances of COVID-19 infections. <i>Applied Soft Computing Journal</i> , 2021, 101, 107039.	4.1	33
390	Assessing Antigen Structural Integrity through Glycosylation Analysis of the SARS-CoV-2 Viral Spike. <i>ACS Central Science</i> , 2021, 7, 586-593.	5.3	68
391	Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. <i>Nature Immunology</i> , 2021, 22, 620-626.	7.0	320
396	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. <i>Cell Reports Medicine</i> , 2021, 2, 100208.	3.3	115
397	COVID-19 Pandemic: Review of Contemporary and Forthcoming Detection Tools. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1049-1082.	1.1	37
398	Diagnosis for COVID-19: current status and future prospects. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 269-288.	1.5	29
399	Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. <i>PLoS ONE</i> , 2021, 16, e0248348.	1.1	102

#	ARTICLE	IF	CITATIONS
400	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 1951.	5.8	54
401	Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays. <i>Scientific Reports</i> , 2021, 11, 6614.	1.6	33
402	Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection. <i>Med</i> , 2021, 2, 281-295.e4.	2.2	153
403	A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. <i>Scientific Reports</i> , 2021, 11, 5198.	1.6	55
404	Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient. , 2021, , .		3
406	Multiplexed Serum Antibody Screening Platform Using Virus Extracts from Endemic <i>Coronaviridae</i> and SARS-CoV-2. <i>ACS Infectious Diseases</i> , 2021, 7, 1596-1606.	1.8	7
408	Effects and Safety of Convalescent Plasma Administration in a Group of Polish Pediatric Patients with COVID-19: A Case Series. <i>Life</i> , 2021, 11, 247.	1.1	8
409	SARS-CoV-2 seroconversion among 4040 Egyptian healthcare workers in 12 resource-limited healthcare facilities: A prospective cohort study. <i>International Journal of Infectious Diseases</i> , 2021, 104, 534-542.	1.5	16
410	SARS-CoV-2 Infection Risk Among Active Duty Military Members Deployed to a Field Hospital in New York City, April 2020. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 308-311.	9.0	18
411	SARS-CoV-2 Antigens Expressed in Plants Detect Antibody Responses in COVID-19 Patients. <i>Frontiers in Plant Science</i> , 2021, 12, 589940.	1.7	31
412	Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection. <i>EBioMedicine</i> , 2021, 65, 103259.	2.7	61
413	Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation. <i>Russian Journal of Infection and Immunity</i> , 2021, 11, 297-323.	0.2	30
414	Chest pain mimicking pulmonary embolism may be a common presentation of COVID-19 in ambulant patients without other typical features of infection. <i>Journal of Internal Medicine</i> , 2021, 290, 349-358.	2.7	6
415	COVID-19 convalescent plasma; time for goal directed therapy?. <i>Transfusion</i> , 2021, 61, 1654-1656.	0.8	2
416	Severe Acute Respiratory Syndrome Coronavirus 2 Viral RNA Load Status and Antibody Distribution Among Patients and Asymptomatic Carriers in Central China. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 559447.	1.8	2
420	Prevalence of SARS-CoV-2 Specific Antibodies in Asymptomatic Hemodialysis Patients. <i>Immunological Investigations</i> , 2022, 51, 993-1004.	1.0	8
421	Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection. <i>Nature Biotechnology</i> , 2021, 39, 928-935.	9.4	106
422	A study on the effects of containment policies and vaccination on the spread of SARS-CoV-2. <i>PLoS ONE</i> , 2021, 16, e0247439.	1.1	5

#	ARTICLE	IF	CITATIONS
423	Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. <i>Immunity</i> , 2021, 54, 557-570.e5.	6.6	153
424	Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 650487.	1.8	3
426	Clinical Application of Serologic Testing for Coronavirus Disease 2019 in Contemporary Cardiovascular Practice. <i>Journal of the American Heart Association</i> , 2021, 10, e019506.	1.6	8
427	Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan. <i>Journal of Medical Virology</i> , 2021, 93, 3211-3218.	2.5	52
428	Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. <i>Nature Communications</i> , 2021, 12, 1403.	5.8	65
429	Production of high-quality SARS-CoV-2 antigens: Impact of bioprocess and storage on glycosylation, biophysical attributes, and ELISA serologic tests performance. <i>Biotechnology and Bioengineering</i> , 2021, 118, 2202-2219.	1.7	27
430	Immunodetection of Lung IgG and IgM Antibodies against SARS-CoV-2 via Enzymatic Liquefaction of Respiratory Samples from COVID-19 Patients. <i>Analytical Chemistry</i> , 2021, 93, 5259-5266.	3.2	8
431	Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities. <i>Scientific Reports</i> , 2021, 11, 5538.	1.6	37
432	COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice. <i>Journal of Virology</i> , 2021, 95, .	1.5	78
434	Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses in vivo and Inhibit Viral Replication in vitro. <i>Frontiers in Immunology</i> , 2021, 12, 613045.	2.2	14
435	N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection. <i>Nature Communications</i> , 2021, 12, 1931.	5.8	104
438	Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts. <i>MSphere</i> , 2021, 6, .	1.3	11
439	IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals. <i>Nature Communications</i> , 2021, 12, 2133.	5.8	44
442	Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection. <i>Frontiers in Immunology</i> , 2021, 12, 614676.	2.2	13
444	Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects. <i>Viruses</i> , 2021, 13, 697.	1.5	36
445	A high-throughput microfluidic nanoimmunoassay for detecting anti-SARS-CoV-2 antibodies in serum or ultralow-volume blood samples. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	44
446	NeutrobodyPlex monitoring SARS-CoV-2 neutralizing immune responses using nanobodies. <i>EMBO Reports</i> , 2021, 22, e52325.	2.0	43
450	Paper-Based Biosensors: Frontiers in Point-of-Care Detection of COVID-19 Disease. <i>Biosensors</i> , 2021, 11, 110.	2.3	39

#	ARTICLE	IF	CITATIONS
451	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , 2021, 12, 2055.	5.8	102
452	Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e25500.	1.2	19
455	Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model. <i>MBio</i> , 2021, 12, .	1.8	62
456	Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19. <i>Cell Reports Medicine</i> , 2021, 2, 100253.	3.3	40
458	Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab220.	0.4	33
459	Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. <i>Lancet Regional Health - Europe</i> , The, 2021, 3, 100014.	3.0	39
460	Systems serology detects functionally distinct coronavirus antibody features in children and elderly. <i>Nature Communications</i> , 2021, 12, 2037.	5.8	125
462	COVID-19 Diagnostic Strategies Part II: Protein-Based Technologies. <i>Bioengineering</i> , 2021, 8, 54.	1.6	14
463	Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. <i>Cell</i> , 2021, 184, 1858-1864.e10.	13.5	332
464	A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics. <i>Journal of Infectious Diseases</i> , 2021, 224, 218-228.	1.9	25
465	Review of the Microbiological Diagnostic Approaches of COVID-19. <i>Frontiers in Public Health</i> , 2021, 9, 592500.	1.3	4
466	Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing. <i>Heliyon</i> , 2021, 7, e06836.	1.4	11
468	Analytical performances of five SARS-CoV-2 whole-blood finger-stick IgG-IgM combined antibody rapid tests. <i>Journal of Virological Methods</i> , 2021, 290, 114067.	1.0	18
469	Sensitive detection of SARS-CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive antibodies in unexposed individuals. <i>Communications Biology</i> , 2021, 4, 486.	2.0	15
470	Anti-SARS-CoV-2 IgM improves clinical sensitivity early in disease course. <i>Clinical Biochemistry</i> , 2021, 90, 1-7.	0.8	11
471	Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers. <i>Scientific Reports</i> , 2021, 11, 7614.	1.6	26
473	An international comparison of anti-SARS-CoV-2 assays used for seroprevalence surveys from blood component providers. <i>Vox Sanguinis</i> , 2021, 116, 946-954.	0.7	6
475	Serological Tests in the Detection of SARS-CoV-2 Antibodies. <i>Diagnostics</i> , 2021, 11, 678.	1.3	9

#	ARTICLE	IF	CITATIONS
477	A Low-Cost SARS-CoV-2 rRBD ELISA to Detect Serostatus in Ecuadorian Population with COVID-19. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1513-1515.	0.6	5
478	Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan. <i>Journal of Medical Microbiology</i> , 2021, 70, .	0.7	4
479	Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients. <i>Viral Immunology</i> , 2021, 34, 201-209.	0.6	31
480	Role of rapid antibody and ELISA tests in the evaluation of serological response in patients with SARS-CoV-2 PCR positivity. <i>Folia Microbiologica</i> , 2021, 66, 579-586.	1.1	3
483	Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	30
484	Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies. <i>Viruses</i> , 2021, 13, 713.	1.5	18
485	Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1444-1452.	1.4	46
486	Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay. <i>International Journal of Infectious Diseases</i> , 2021, 105, 21-25.	1.5	43
487	Early Detection of SARS-CoV-2 Seroconversion in Humans with Aggregation-Induced Near-Infrared Emission Nanoparticle-Labeled Lateral Flow Immunoassay. <i>ACS Nano</i> , 2021, 15, 8996-9004.	7.3	109
488	Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya. <i>Clinical Infectious Diseases</i> , 2022, 74, 288-293.	2.9	36
489	IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4951.	1.8	20
491	Parameters of immunoglobulin extraction from dried blood spot cards and immunoassays for detection of antibody response to pathogens including the novel SARS-CoV-2. <i>Journal of Immunological Methods</i> , 2021, 492, 112996.	0.6	1
493	Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B.1.351 Isolates in Microneutralization Assays. <i>Viruses</i> , 2021, 13, 996.	1.5	14
494	A Generic, Scalable, and Rapid Time-Resolved Förster Resonance Energy Transfer-Based Assay for Antigen Detection of SARS-CoV-2 as a Proof of Concept. <i>MBio</i> , 2021, 12, .	1.8	40
495	Electrochemical diagnostics of infectious viral diseases: Trends and challenges. <i>Biosensors and Bioelectronics</i> , 2021, 180, 113112.	5.3	63
496	Conserved and Novel Mouse CD8 T Cell Epitopes within SARS-CoV-2 Spike Receptor Binding Domain Protein Identified following Subunit Vaccination. <i>Journal of Immunology</i> , 2021, 206, 2503-2507.	0.4	11
497	Facile Determination of COVID-19 Seroconversion via Nonradiative Energy Transfer. <i>ACS Sensors</i> , 2021, 6, 2136-2140.	4.0	5
498	TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. <i>Cell</i> , 2021, 184, 2618-2632.e17.	13.5	80

#	ARTICLE	IF	CITATIONS
499	Vaccination strategy and anti - SARS-CoV-2â€™S titers in healthcare workers of the INT â€“ IRCCS â€œFondazione Pascaleâ€•Cancer Center (Naples, Italy). <i>Infectious Agents and Cancer</i> , 2021, 16, 32.	1.2	15
500	Capacidad de respuesta inmunitaria al COVID-19 en pacientes en hemodi�lisis. <i>Revista De Investigaci�n Y Educaci�n En Ciencias De La Salud (RIECS)</i> , 2021, 6, 75-81.	0.0	0
504	Adaptive immune responses to SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 1-8.	6.6	6
508	Comparative Analysis of Antigen-Specific Antiâ€“SARS-CoV-2 Antibody Isotypes in COVID-19 Patients. <i>Journal of Immunology</i> , 2021, 206, 2393-2401.	0.4	19
509	A simple, sensitive, and lowâ€“cost FACS assay for detecting antibodies against the native SARSâ€“CoVâ€“2 spike protein. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 905-917.	1.3	5
510	New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic. <i>Archives of Disease in Childhood</i> , 2022, 107, 180-185.	1.0	91
511	Testing at scale during the COVID-19 pandemic. <i>Nature Reviews Genetics</i> , 2021, 22, 415-426.	7.7	261
512	Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. <i>Cell Reports Medicine</i> , 2021, 2, 100288.	3.3	121
513	Multichannel Immunosensor Platform for the Rapid Detection of SARS-CoV-2 and Influenza A(H1N1) Virus. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 22262-22270.	4.0	41
515	Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population. <i>BMC Infectious Diseases</i> , 2021, 21, 443.	1.3	16
516	Different Laboratory Diagnosis Methods of COVID-19: A Systematic Review. <i>Archives of Clinical Infectious Diseases</i> , 2021, 16, .	0.1	6
518	DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist. <i>PLoS Pathogens</i> , 2021, 17, e1009576.	2.1	133
519	CD8+ T�cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. <i>Immunity</i> , 2021, 54, 1066-1082.e5.	6.6	106
521	Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. <i>Thrombosis Research</i> , 2021, 201, 100-112.	0.8	42
524	Antibodies: what makes us stronger. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3551-3553.	1.4	1
525	A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests. <i>EBioMedicine</i> , 2021, 67, 103348.	2.7	34
526	Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. <i>Nature Communications</i> , 2021, 12, 2670.	5.8	297
527	Delayed production of neutralizing antibodies correlates with fatal COVID-19. <i>Nature Medicine</i> , 2021, 27, 1178-1186.	15.2	183

#	ARTICLE	IF	CITATIONS
529	Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors. <i>Frontiers in Microbiology</i> , 2021, 12, 661187.	1.5	21
530	Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys. <i>Journal of Infectious Diseases</i> , 2021, 224, 407-414.	1.9	43
531	COVID-19 serological survey using micro blood sampling. <i>Scientific Reports</i> , 2021, 11, 9475.	1.6	12
534	Prevalence and Clinical Profile of Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Farmworkers, California, USA, June–November 2020. <i>Emerging Infectious Diseases</i> , 2021, 27, 1330-1342.	2.0	23
536	Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens. <i>Human Antibodies</i> , 2021, 29, 109-113.	0.6	7
537	Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure. <i>JCI Insight</i> , 2021, 6, .	2.3	24
538	Flow cytometry detection of sustained humoral immune response (IgG+IgA) against native spike glycoprotein in asymptomatic/mild SARS-CoV-2 infection. <i>Scientific Reports</i> , 2021, 11, 10716.	1.6	3
544	Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay. <i>Diagnostics</i> , 2021, 11, 994.	1.3	17
545	A simplified alternative diagnostic algorithm for SARS-CoV-2 suspected symptomatic patients and confirmed close contacts (asymptomatic): A consensus of Latin American experts. <i>International Journal of Infectious Diseases</i> , 2021, , .	1.5	0
548	Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva. <i>Immunology</i> , 2021, 164, 135-147.	2.0	35
549	Multiplexed, microscale, microarray-based serological assay for antibodies against all human-relevant coronaviruses. <i>Journal of Virological Methods</i> , 2021, 291, 114111.	1.0	11
550	International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Responses. <i>Vox Sanguinis</i> , 2021, 116, e71-e120.	0.7	3
551	Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. <i>Nature Communications</i> , 2021, 12, 3109.	5.8	118
552	Durability of the humoral immune response in recovered COVID-19 patients. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 2802-2806.	1.8	11
553	Diverse functional autoantibodies in patients with COVID-19. <i>Nature</i> , 2021, 595, 283-288.	13.7	619
554	Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1339-1344.	0.5	202
555	Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform. <i>PLoS ONE</i> , 2021, 16, e0252628.	1.1	11
556	Machine learning and computation-enabled intelligent sensor design. <i>Nature Machine Intelligence</i> , 2021, 3, 556-565.	8.3	86

#	ARTICLE	IF	CITATIONS
558	COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men. <i>Journal of Infectious Diseases</i> , 2021, 224, 793-797.	1.9	30
560	Application of newly developed SARS-CoV2 serology test along with real-time PCR for early detection in health care workers and on-time plasma donation. <i>Gene Reports</i> , 2021, 23, 101140.	0.4	13
561	Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 886-891.	2.8	51
562	Immunological imprinting of the antibody response in COVID-19 patients. <i>Nature Communications</i> , 2021, 12, 3781.	5.8	149
563	Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab314.	0.4	12
564	Early and High SARS-CoV-2 Neutralizing Antibodies Are Associated with Severity in COVID-19 Patients from India. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	9
565	Rapid and accurate agglutination-based testing for SARS-CoV-2 antibodies. <i>Cell Reports Methods</i> , 2021, 1, 100011.	1.4	11
566	An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory. <i>ACS Central Science</i> , 2021, 7, 1191-1204.	5.3	34
567	Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination. <i>Vaccines</i> , 2021, 9, 587.	2.1	6
568	SARS-CoV-2 Peptide Bioconjugates Designed for Antibody Diagnostics. <i>Bioconjugate Chemistry</i> , 2021, 32, 1606-1616.	1.8	7
569	A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro. <i>Viruses</i> , 2021, 13, 1055.	1.5	4
570	Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19. <i>Scientific Reports</i> , 2021, 11, 13308.	1.6	50
571	Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection. <i>Clinical Microbiology Reviews</i> , 2021, 34, .	5.7	205
572	Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients. <i>IScience</i> , 2021, 24, 102489.	1.9	11
573	Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry. <i>Scientific Reports</i> , 2021, 11, 12448.	1.6	22
574	A Cross-Sectional Study of SARS-CoV-2 Seroprevalence between Fall 2020 and February 2021 in Allegheny County, Western Pennsylvania, USA. <i>Pathogens</i> , 2021, 10, 710.	1.2	8
576	Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses. <i>ACS Nano</i> , 2021, 15, 11180-11191.	7.3	60
578	N-Glycosylation of the SARS-CoV-2 Receptor Binding Domain Is Important for Functional Expression in Plants. <i>Frontiers in Plant Science</i> , 2021, 12, 689104.	1.7	34

#	ARTICLE	IF	CITATIONS
579	Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya. <i>Nature Communications</i> , 2021, 12, 3966.	5.8	40
580	The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe. <i>Covid</i> , 2021, 1, 20-38.	0.7	22
581	Diagnostic and analytical performance evaluation of ten commercial assays for detecting SARS-CoV-2 humoral immune response. <i>Journal of Immunological Methods</i> , 2021, 493, 113043.	0.6	10
582	Persisting Antibody Response to SARS-CoV-2 in a Local Austrian Population. <i>Frontiers in Medicine</i> , 2021, 8, 653630.	1.2	8
584	Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. <i>Immunity</i> , 2021, 54, 1290-1303.e7.	6.6	101
585	Multiplex quantitative detection of SARS-CoV-2 specific IgG and IgM antibodies based on DNA-assisted nanopore sensing. <i>Biosensors and Bioelectronics</i> , 2021, 181, 113134.	5.3	43
586	A comparative review of immunoassays for COVID-19 detection. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 573-599.	1.3	74
587	Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 3695.	5.8	32
589	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. <i>Cells</i> , 2021, 10, 1412.	1.8	6
591	Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test. <i>Science Advances</i> , 2021, 7, .	4.7	42
592	Heparan Sulfate Proteoglycans as Attachment Factor for SARS-CoV-2. <i>ACS Central Science</i> , 2021, 7, 1009-1018.	5.3	113
593	Human IgG and IgA responses to COVID-19 mRNA vaccines. <i>PLoS ONE</i> , 2021, 16, e0249499.	1.1	148
594	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021, 595, 426-431.	13.7	610
595	High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay. <i>Scientific Reports</i> , 2021, 11, 12330.	1.6	12
596	Green chemistry and coronavirus. <i>Sustainable Chemistry and Pharmacy</i> , 2021, 21, 100415.	1.6	29
598	COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 3991.	5.8	241
599	A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0019321.	1.8	20
600	Young infants exhibit robust functional antibody responses and restrained IFN- γ production to SARS-CoV-2. <i>Cell Reports Medicine</i> , 2021, 2, 100327.	3.3	29

#	ARTICLE	IF	CITATIONS
601	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. <i>Nature</i> , 2021, 595, 278-282.	13.7	154
602	Long COVID in a prospective cohort of home-isolated patients. <i>Nature Medicine</i> , 2021, 27, 1607-1613.	15.2	453
603	Unified platform for genetic and serological detection of COVID-19 with single-molecule technology. <i>PLoS ONE</i> , 2021, 16, e0255096.	1.1	5
608	Current vaccine technology with an emphasis on recombinant measles virus as a new perspective for vaccination against SARS-CoV-2. <i>Euro-Mediterranean Journal for Environmental Integration</i> , 2021, 6, 61.	0.6	0
609	SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. <i>Journal of Immunology</i> , 2021, 207, 878-887.	0.4	30
611	Development of rapid and cost-effective top-loading device for the detection of anti-SARS-CoV-2 IgG/IgM antibodies. <i>Scientific Reports</i> , 2021, 11, 14926.	1.6	1
612	Cohabitation With a Known Coronavirus Disease 2019 Case Is Associated With Greater Antibody Concentration and Symptom Severity in a Community-Based Sample of Seropositive Adults. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab244.	0.4	6
614	Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern. <i>JCI Insight</i> , 2021, 6, .	2.3	32
615	Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing. <i>Translational Medicine Communications</i> , 2021, 6, 13.	0.5	1
617	Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0253977.	1.1	35
618	Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study. <i>Microorganisms</i> , 2021, 9, 1643.	1.6	19
619	Expression of SARS-CoV-2 surface glycoprotein fragment 319â€“640 in <i>E. coli</i> , and its refolding and purification. <i>Protein Expression and Purification</i> , 2021, 183, 105861.	0.6	25
620	Performance of Three SARS-CoV-2 Immunoassays, Three Rapid Lateral Flow Tests, and a Novel Bead-Based Affinity Surrogate Test for the Detection of SARS-CoV-2 Antibodies in Human Serum. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0031921.	1.8	10
621	Enhancing the Stability of COVIDâ€“19 Serological Assay through Metalâ€“Organic Framework Encapsulation. <i>Advanced Healthcare Materials</i> , 2021, 10, 2100410.	3.9	4
623	Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity. <i>Viruses</i> , 2021, 13, 1371.	1.5	11
624	SARS-CoV2 IgG antibody: Seroprevalence among health care workers. <i>Clinical Epidemiology and Global Health</i> , 2021, 11, 100766.	0.9	9
626	Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020. <i>PLoS ONE</i> , 2021, 16, e0254667.	1.1	4
629	Immunological aspects of SARS-CoV-2 coronavirus damage. <i>Vestnik of Russian Military Medical Academy</i> , 2021, 23, 187-198.	0.1	9

#	ARTICLE	IF	CITATIONS
631	High-resolution serum proteome trajectories in COVID-19 reveal patient-specific seroconversion. <i>EMBO Molecular Medicine</i> , 2021, 13, e14167.	3.3	92
632	Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses. <i>PLoS ONE</i> , 2021, 16, e0254367.	1.1	17
633	SARS-CoV-2 Receptor Binding Domain as a Stable-Potential Target for SARS-CoV-2 Detection by Surface-Enhanced Raman Spectroscopy. <i>Sensors</i> , 2021, 21, 4617.	2.1	15
635	Disease-dependent interaction policies to support health and economic outcomes during the COVID-19 epidemic. <i>IScience</i> , 2021, 24, 102710.	1.9	12
636	Assessment of serological assays for identifying high titer convalescent plasma. <i>Transfusion</i> , 2021, 61, 2658-2667.	0.8	7
638	Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine. <i>Science Advances</i> , 2021, 7, .	4.7	60
639	Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	180
640	Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography. <i>Frontiers in Immunology</i> , 2021, 12, 696370.	2.2	14
641	Seroprevalence of SARS-CoV-2 antibodies in health-care workers at a tertiary paediatric hospital. <i>Journal of Paediatrics and Child Health</i> , 2021, 57, 1136-1139.	0.4	2
643	Ultrasensitive, high-throughput, and rapid simultaneous detection of SARS-CoV-2 antigens and IgG/IgM antibodies within 10 min through an immunoassay biochip. <i>Mikrochimica Acta</i> , 2021, 188, 262.	2.5	23
644	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. <i>Science Advances</i> , 2021, 7, .	4.7	117
645	Contributions of the international plant science community to the fight against human infectious diseases – part 1: epidemic and pandemic diseases. <i>Plant Biotechnology Journal</i> , 2021, 19, 1901-1920.	4.1	44
646	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993.	1.8	136
648	Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in waters via surface enhanced Raman scattering (SERS). <i>Water Research</i> , 2021, 200, 117243.	5.3	77
649	SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. <i>Cell</i> , 2021, 184, 3936-3948.e10.	13.5	241
650	Coronavirus Disease 2019 (COVID-19) Diagnostic Tools: A Focus on Detection Technologies and Limitations. <i>Current Issues in Molecular Biology</i> , 2021, 43, 728-748.	1.0	26
651	Diverse high-affinity DNA aptamers for wild-type and B.1.1.7 SARS-CoV-2 spike proteins from a pre-structured DNA library. <i>Nucleic Acids Research</i> , 2021, 49, 7267-7279.	6.5	77
653	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 4598.	5.8	88

#	ARTICLE	IF	CITATIONS
656	Characterization of the Diagnostic Performance of a Novel COVID-19 PETIA in Comparison to Four Routine N-, S- and RBD-Antigen Based Immunoassays. <i>Diagnostics</i> , 2021, 11, 1332.	1.3	4
657	Humoral immune responses in hospitalized COVID-19 patients. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 4055-4061.	1.8	3
658	Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic. <i>ACS Nanoscience Au</i> , 2021, 1, 15-37.	2.0	9
659	SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. <i>Nature Microbiology</i> , 2021, 6, 1188-1198.	5.9	314
660	SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes. <i>Microorganisms</i> , 2021, 9, 1744.	1.6	16
661	Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 723585.	2.2	11
662	Delayed neutralizing antibody response in the acute phase correlates with severe progression of COVID-19. <i>Scientific Reports</i> , 2021, 11, 16535.	1.6	12
663	Validation of high-throughput, semiquantitative solid-phase SARS-CoV-2 serology assays in serum and dried blood spot matrices. <i>Bioanalysis</i> , 2021, 13, 1183-1193.	0.6	7
664	Immunity to SARS-CoV-2 induced by infection or vaccination. <i>Journal of Internal Medicine</i> , 2022, 291, 32-50.	2.7	97
665	Associations of SARS-CoV-2 serum IgG with occupation and demographics of military personnel. <i>PLoS ONE</i> , 2021, 16, e0251114.	1.1	1
666	Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1862-1864.	0.9	19
667	COVID-19 clinical and laboratory diagnosis overview. <i>Journal of the Egyptian Public Health Association</i> , The, 2021, 96, 25.	1.0	7
669	Single-antigen multi-antigen serological test for comprehensive evaluation of SARS-CoV-2 patients by flow cytometry. <i>European Journal of Immunology</i> , 2021, 51, 2633-2640.	1.6	9
671	Recent Advances in Novel Lateral Flow Technologies for Detection of COVID-19. <i>Biosensors</i> , 2021, 11, 295.	2.3	66
674	Longitudinal COVID-19 Surveillance and Characterization in the Workplace with Public Health and Diagnostic Endpoints. <i>MSphere</i> , 2021, 6, e0054221.	1.3	5
676	Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19. <i>Vaccines</i> , 2021, 9, 928.	2.1	12
679	Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. <i>Cancer Cell</i> , 2021, 39, 1028-1030.	7.7	176
681	Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation. <i>Vaccine</i> , 2021, 39, 5055-5063.	1.7	21

#	ARTICLE	IF	CITATIONS
682	Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. <i>ELife</i> , 2021, 10, .	2.8	267
683	Healthcare-associated transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) among Thai healthcare personnel who receive 2 doses of a coronavirus disease 2019 (COVID-19) vaccine: A call for considering a booster dose. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-2.	1.0	4
686	SARS-CoV-2 RNA and antibody detection in breast milk from a prospective multicentre study in Spain. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2022, 107, 216-221.	1.4	33
687	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. <i>Immunity</i> , 2021, 54, 2385-2398.e10.	6.6	46
688	Clinical Spectrum of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Protection From Symptomatic Reinfection. <i>Clinical Infectious Diseases</i> , 2022, 75, e257-e266.	2.9	33
689	Combating the progression of novel coronavirus SARS-CoV-2 infectious Disease: Current state and future prospects in molecular diagnostic and drug discovery. <i>Current Molecular Medicine</i> , 2021, 21, .	0.6	6
690	Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers. <i>Clinica Chimica Acta</i> , 2021, 519, 60-63.	0.5	74
692	SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic. <i>Viruses</i> , 2021, 13, 1648.	1.5	22
693	Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study. <i>Science Immunology</i> , 2021, 6, .	5.6	20
694	Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss) Tj ETQq1 1 0.784314 rgBT /Overl	0.8	7
696	Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. <i>Cell Reports</i> , 2021, 36, 109518.	2.9	142
697	Mass spectrometry-based proteomics in basic and translational research of SARS-CoV-2 coronavirus and its emerging mutants. <i>Clinical Proteomics</i> , 2021, 18, 19.	1.1	12
698	B cells promote CD8 T cell primary and memory responses to subunit vaccines. <i>Cell Reports</i> , 2021, 36, 109591.	2.9	21
699	SARS-CoV-2 Antibody Testing: Where Are We Now?. <i>Laboratory Medicine</i> , 2021, , .	0.8	2
701	Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect <i>In Vivo</i> in a Mouse Model in a Neutralization-Dependent Manner. <i>MBio</i> , 2021, 12, e0100221.	1.8	7
702	The association between obesity and peak antibody titer response in COVID-19 infection. <i>Obesity</i> , 2021, 29, 1547-1553.	1.5	35
703	Evaluation of rapid antibody test and chest computed tomography results of COVID-19 patients: A retrospective study. <i>Journal of Medical Virology</i> , 2021, 93, 6582-6587.	2.5	5
705	Development and Evaluation of a Set of Spike and Receptor Binding Domain-Based Enzyme-Linked Immunosorbent Assays for SARS-CoV-2 Serological Testing. <i>Diagnostics</i> , 2021, 11, 1506.	1.3	10

#	ARTICLE	IF	CITATIONS
706	Structure of herd immunity to SARS-COV-2 in the Krasnoyarsk region population in the COVID-19 epidemic. <i>Acta Biomedica Scientifica</i> , 2021, 6, 227-238.	0.1	2
707	Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein. <i>MSphere</i> , 2021, 6, e0064721.	1.3	40
709	Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history. <i>Scientific Reports</i> , 2021, 11, 17325.	1.6	27
710	Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab420.	0.4	12
711	Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression. <i>Human Pathology</i> , 2021, 114, 110-119.	1.1	32
712	Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. <i>PLoS Pathogens</i> , 2021, 17, e1009772.	2.1	74
713	Seroprevalence of COVID-19 IgG antibodies among healthcare workers of Pakistan: a cross-sectional study assessing exposure to COVID-19 and identification of high-risk subgroups. <i>BMJ Open</i> , 2021, 11, e046276.	0.8	7
714	Identification of lectin receptors for conserved SARS-CoV-2 glycosylation sites. <i>EMBO Journal</i> , 2021, 40, e108375.	3.5	44
715	An Approach to Transitioning Undergraduate Biochemistry Laboratory Courses Online. <i>The Biophysicist</i> , 2021, 2, 33-37.	0.1	1
716	Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. <i>EClinicalMedicine</i> , 2021, 38, 101018.	3.2	77
717	Household level SARS-CoV-2 sero-epidemiology in a high prevalence group of adults and children-implications for community infection control. <i>American Journal of Infection Control</i> , 2021, 49, 1438-1440.	1.1	0
718	A Linkage-specific Sialic Acid Labeling Strategy Reveals Different Site-specific Glycosylation Patterns in SARS-CoV-2 Spike Protein Produced in CHO and HEK Cell Substrates. <i>Frontiers in Chemistry</i> , 2021, 9, 735558.	1.8	12
719	Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients. <i>Scientific Reports</i> , 2021, 11, 17642.	1.6	41
721	Development of in-house, indirect ELISAs for the detection of SARS-CoV-2 spike protein-associated serology in COVID-19 patients in Panama. <i>PLoS ONE</i> , 2021, 16, e0257351.	1.1	6
722	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. <i>Immunity</i> , 2021, 54, 2159-2166.e6.	6.6	52
723	Impact of Specific N-Glycan Modifications on the Use of Plant-Produced SARS-CoV-2 Antigens in Serological Assays. <i>Frontiers in Plant Science</i> , 2021, 12, 747500.	1.7	8
724	Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera. <i>Microbiology Spectrum</i> , 2021, 9, e0045821.	1.2	3
725	Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. <i>Science Immunology</i> , 2021, 6, eabl4509.	5.6	141

#	ARTICLE	IF	CITATIONS
726	Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0052721.	1.8	71
727	Differential Antibody Response to SARS-CoV-2 Antigens in Recovered and Deceased Iranian COVID-19 Patients. <i>Viral Immunology</i> , 2021, 34, 708-713.	0.6	2
728	Anti-SARS-CoV-2 immunoglobulin profile in patients with celiac disease living in a high incidence area. <i>Digestive and Liver Disease</i> , 2022, 54, 3-9.	0.4	8
730	SARS-CoV-2 seroprevalence and associated factors in Manaus, Brazil: baseline results from the DETECTCoV-19 cohort study. <i>International Journal of Infectious Diseases</i> , 2021, 110, 141-150.	1.5	32
731	Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffolds. <i>Bioengineering and Translational Medicine</i> , 2021, 6, e10253.	3.9	19
732	SARS-CoV-2 infection shortly after BNT162b2 vaccination results in high anti-spike antibody levels in nursing home residents and staff. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1702-1706.	1.3	15
733	The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 737083.	2.2	18
734	New-onset IgG autoantibodies in hospitalized patients with COVID-19. <i>Nature Communications</i> , 2021, 12, 5417.	5.8	286
735	Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. <i>Science</i> , 2021, 374, eabj9853.	6.0	236
736	SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans. <i>Frontiers in Immunology</i> , 2021, 12, 728021.	2.2	20
737	Differential pre-pandemic breast milk IgA reactivity against SARS-CoV-2 and circulating human coronaviruses in Ugandan and American mothers. <i>International Journal of Infectious Diseases</i> , 2021, 112, 165-172.	1.5	6
738	Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response. <i>Microbiology Spectrum</i> , 2021, 9, e0073321.	1.2	22
739	Recombinant Protein Expression and Purification of N, S1, and RBD of SARS-CoV-2 from Mammalian Cells and Their Potential Applications. <i>Diagnostics</i> , 2021, 11, 1808.	1.3	12
740	Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis. <i>JAMA Network Open</i> , 2021, 4, e2123622.	2.8	49
741	SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1. <i>Vaccine</i> , 2021, 39, 5769-5779.	1.7	23
744	SARS-CoV-2 integral membrane proteins shape the serological responses of patients with COVID-19. <i>IScience</i> , 2021, 24, 103185.	1.9	13
745	The use of nanobodies in a sensitive ELISA test for SARS-CoV-2 Spike 1 protein. <i>Royal Society Open Science</i> , 2021, 8, 211016.	1.1	19
746	Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples. <i>Journal of Immunological Methods</i> , 2021, 499, 113160.	0.6	12

#	ARTICLE	IF	CITATIONS
748	A Hemagglutination-Based Semiquantitative Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0118621.	1.8	6
749	Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. <i>MBio</i> , 2021, 12, e0190821.	1.8	32
751	Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. <i>Cell Reports</i> , 2021, 37, 109822.	2.9	35
752	Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. <i>JCI Insight</i> , 2021, 6, .	2.3	45
754	A rapid test recognizing mucosal SARS-CoV-2-specific antibodies distinguishes prodromal from convalescent COVID-19. <i>IScience</i> , 2021, 24, 103194.	1.9	1
755	Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 1261-1269.	2.0	84
756	Serological assessment of SARS-CoV-2 infection during the first wave of the pandemic in Louisville Kentucky. <i>Scientific Reports</i> , 2021, 11, 18285.	1.6	10
757	Seroprevalence of Immunoglobulin-G Antibody Among Confirm Cases of COVID-19. <i>Cureus</i> , 2021, 13, e17956.	0.2	1
758	Direct detection of human adenovirus or SARS-CoV-2 with ability to inform infectivity using DNA aptamer-nanopore sensors. <i>Science Advances</i> , 2021, 7, eabh2848.	4.7	87
759	Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms. <i>IScience</i> , 2021, 24, 102937.	1.9	10
760	Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1481-1492.e2.	1.5	43
761	COVID-19 infection after mRNA 1273 vaccine: review of the most frequently asked questions. <i>Infezioni in Medicina</i> , 2021, 29, 305-311.	0.7	2
762	Durable Antibody Responses in Staff at Two Long-Term Care Facilities, during and Post SARS-CoV-2 Outbreaks. <i>Microbiology Spectrum</i> , 2021, 9, e0022421.	1.2	8
763	Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. <i>Wellcome Open Research</i> , 0, 6, 220.	0.9	6
766	Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines. <i>PLoS ONE</i> , 2021, 16, e0252849.	1.1	11
768	Highly active engineered IgG3 antibodies against SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	48
769	Evaluation of spike protein antigens for SARS-CoV-2 serology. <i>Journal of Virological Methods</i> , 2021, 296, 114222.	1.0	10
770	Contribution of rapid lateral flow assays from capillary blood specimens to the diagnosis of COVID-19 in symptomatic healthcare workers: a pilot study in a university hospital, Paris, France. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115430.	0.8	0

#	ARTICLE	IF	CITATIONS
771	Humoral immune mechanisms involved in protective and pathological immunity during COVID-19. <i>Human Immunology</i> , 2021, 82, 733-745.	1.2	47
772	A rapid quantitative on-site coronavirus disease 19 serological test. <i>Biosensors and Bioelectronics</i> , 2021, 191, 113406.	5.3	10
773	Current status, advances, challenges and perspectives on biosensors for COVID-19 diagnosis in resource-limited settings. <i>Sensors and Actuators Reports</i> , 2021, 3, 100025.	2.3	24
774	An electrochemical immunosensor using SARS-CoV-2 spike protein-nickel hydroxide nanoparticles bio-conjugate modified SPCE for ultrasensitive detection of SARS-CoV-2 antibodies. <i>Microchemical Journal</i> , 2021, 170, 106718.	2.3	47
775	One-pot pre-coated interface proximity extension assay for ultrasensitive co-detection of anti-SARS-CoV-2 antibodies and viral RNA. <i>Biosensors and Bioelectronics</i> , 2021, 193, 113535.	5.3	13
776	Ultra-sensitive and fast optical detection of the spike protein of the SARS-CoV-2 using AgNPs/SiNWs nanohybrid based sensors. <i>Surfaces and Interfaces</i> , 2021, 27, 101454.	1.5	27
777	SERS-based lateral flow immunoassay for sensitive and simultaneous detection of anti-SARS-CoV-2 IgM and IgG antibodies by using gap-enhanced Raman nanotags. <i>Sensors and Actuators B: Chemical</i> , 2021, 348, 130706.	4.0	57
778	CRISPR-Cas based virus detection: Recent advances and perspectives. <i>Biosensors and Bioelectronics</i> , 2021, 193, 113541.	5.3	110
779	Magnetofluidic immuno-PCR for point-of-care COVID-19 serological testing. <i>Biosensors and Bioelectronics</i> , 2022, 195, 113656.	5.3	18
781	Demographic Characteristics of Adults with IgG Antibodies to Prior Symptomatic SARS-CoV-2 Infection. <i>Journal of General Internal Medicine</i> , 2021, 36, 1156-1158.	1.3	0
782	Preventing Coronavirus Disease 2019 in Kidney Transplant Recipients: Where Should We Begin?. <i>Nephron</i> , 2021, 145, 280-284.	0.9	2
784	Modifying laboratory testing via home brew during the COVID-19 pandemic. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e93.	0.3	3
785	Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests. <i>Epidemiology and Infection</i> , 2021, 149, e140.	1.0	9
788	Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma. <i>Journal of Infectious Diseases</i> , 2021, 223, 743-751.	1.9	17
789	The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 Pandemic. <i>Academic Pathology</i> , 2021, 8, 23742895211006818.	0.7	5
794	Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. <i>PLoS ONE</i> , 2021, 16, e0245382.	1.1	14
795	Development and Characterization of a Quantitative ELISA to Detect Anti-SARS-CoV-2 Spike Antibodies. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
797	Current advances in the detection of COVID-19 and evaluation of the humoral response. <i>Analyst</i> , The, 2021, 146, 382-402.	1.7	25

#	ARTICLE	IF	CITATIONS
798	Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. <i>Frontiers in Immunology</i> , 2020, 11, 628971.	2.2	51
799	Microscopy-based assay for semi-quantitative detection of SARS-CoV-2 specific antibodies in human sera. <i>BioEssays</i> , 2021, 43, e2000257.	1.2	22
800	The outlook for diagnostic purposes of the 2019 novel coronavirus disease. <i>Journal of Cellular Physiology</i> , 2020, 235, 9211-9229.	2.0	35
801	6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 351-358.	1.0	10
802	Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis. <i>ACS Omega</i> , 2021, 6, 85-102.	1.6	54
803	SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. <i>Nature</i> , 2020, 587, 270-274.	13.7	1,115
804	Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of Infectious Diseases</i> , 2021, 223, 957-970.	1.9	64
805	Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting. <i>Journal of Infectious Diseases</i> , 2021, 223, 971-980.	1.9	20
806	Universal Polymerase Chain Reaction and Antibody Testing Demonstrate Little to No Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in a Rural Community. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa531.	0.4	9
807	Breast Reconstruction in a Coronavirus Disease 2019 Hub. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2020, 8, e3043.	0.3	12
808	Diagnostic testing for SARS-CoV-2/COVID19. <i>Current Opinion in Pediatrics</i> , 2021, 33, 122-128.	1.0	18
809	Identification of Immunohistochemical Reagents for In Situ Protein Expression Analysis of Coronavirus-associated Changes in Human Tissues. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 5-12.	0.6	26
936	Accuracy of serological testing for SARS-CoV-2 antibodies: First results of a large mixed-method evaluation study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 853-865.	2.7	34
937	A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. <i>FEBS Journal</i> , 2020, 287, 3633-3650.	2.2	192
938	Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. <i>Science Immunology</i> , 2020, 5, .	5.6	172
939	Genome sequencing and the diagnosis of novel coronavirus (SARS-COV-2) in Africa: how far are we?. <i>Pan African Medical Journal</i> , 2020, 36, 80.	0.3	9
940	A simple protein-based surrogate neutralization assay for SARS-CoV-2. <i>JCI Insight</i> , 2020, 5, .	2.3	193
941	Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. <i>JCI Insight</i> , 2020, 5, .	2.3	130

#	ARTICLE	IF	CITATIONS
942	Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. <i>Journal of Clinical Investigation</i> , 2020, 130, 6728-6738.	3.9	172
943	COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. <i>Journal of Clinical Investigation</i> , 2020, 130, 6366-6378.	3.9	97
944	Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population. <i>F1000Research</i> , 2020, 9, 285.	0.8	19
945	Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population. <i>F1000Research</i> , 2020, 9, 285.	0.8	20
946	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. <i>Wellcome Open Research</i> , 2020, 5, 139.	0.9	179
947	Capillary whole-blood IgG-IgM COVID-19 self-test as a serological screening tool for SARS-CoV-2 infection adapted to the general public. <i>PLoS ONE</i> , 2020, 15, e0240779.	1.1	9
948	Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis. <i>PLoS ONE</i> , 2020, 15, e0241164.	1.1	47
949	Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study. <i>PLoS ONE</i> , 2020, 15, e0242917.	1.1	12
950	Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome. <i>PLoS ONE</i> , 2020, 15, e0243029.	1.1	22
951	mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2. <i>PLoS Pathogens</i> , 2020, 16, e1009163.	2.1	24
952	SARS-CoV-2 serosurvey in health care workers of the Veneto Region. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 2107-2111.	1.4	64
953	IFCC Interim Guidelines on Serological Testing of Antibodies against SARS-CoV-2. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 2001-2008.	1.4	59
959	Mouse Model of SARS-CoV-2 Reveals Inflammatory Role of Type I Interferon Signaling. <i>SSRN Electronic Journal</i> , 2020, , 3628297.	0.4	3
960	The Loss of Bcl-6 Expressing T Follicular Helper Cells and the Absence of Germinal Centers in COVID-19. <i>SSRN Electronic Journal</i> , 2020, , 3652322.	0.4	20
961	An Affordable Anti-SARS-COV-2 Spike Protein Elisa Test for Early Detection of IgG Seroconversion Suited for Large-Scale Surveillance Studies in Low-Income Countries. <i>SSRN Electronic Journal</i> , 0, , .	0.4	5
962	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future. <i>Indian Journal of Ophthalmology</i> , 2020, 68, 693.	0.5	78
963	Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia. <i>ELife</i> , 2020, 9, .	2.8	26
964	Collaborative networks enable the rapid establishment of serological assays for SARS-CoV-2 during nationwide lockdown in New Zealand. <i>PeerJ</i> , 2020, 8, e9863.	0.9	12

#	ARTICLE	IF	CITATIONS
965	The Possibility and Cause of Relapse After Previously Recovering From COVID-19: A Systematic Review. <i>Cureus</i> , 2020, 12, e10264.	0.2	10
966	Germinal Center-Induced Immunity Is Correlated With Protection Against SARS-CoV-2 Reinfection But Not Lung Damage. <i>Journal of Infectious Diseases</i> , 2021, 224, 1861-1872.	1.9	6
967	Comprehensive serological strategy for the diagnosis and monitoring of SARS-CoV-2. From infection to vaccine control. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 44-45.	0.5	0
968	Praxis of Technology and Tools in COVID-19 Response. <i>Research Journal of Pharmacy and Technology</i> , 2021, , 4808-4814.	0.2	1
969	Persistence of infectious SARS-CoV-2 particles for up to 37 days in patients with mild COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2053-2066.	2.7	8
970	Serum IgG anti-SARS-CoV-2 Binding Antibody Level Is Strongly Associated With IgA and Functional Antibody Levels in Adults Infected With SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 693462.	2.2	6
971	Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission. <i>Science Immunology</i> , 2021, 6, eabm3131.	5.6	37
972	Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination. <i>Journal of Immunological Methods</i> , 2021, 499, 113165.	0.6	6
973	Spike-based COVID-19 immunization increases antibodies to nucleocapsid antigen. <i>Translational Research</i> , 2022, 240, 26-32.	2.2	12
974	Non-Invasive Antibody Assessment in Saliva to Determine SARS-CoV-2 Exposure in Young Children. <i>Frontiers in Immunology</i> , 2021, 12, 753435.	2.2	13
975	Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. <i>Nature</i> , 2021, 600, 523-529.	13.7	194
976	Expression and characterization of SARS-CoV-2 spike proteins. <i>Nature Protocols</i> , 2021, 16, 5339-5356.	5.5	31
978	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021, 600, 517-522.	13.7	239
979	<scp>COVID</scp>â€19 Vaccine Response in People with Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 89-100.	2.8	119
980	ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. <i>Nature Communications</i> , 2021, 12, 5868.	5.8	52
986	An Insight Into Detection Pathways/Biosensors of Highly Infectious Coronaviruses. <i>Molecular Biotechnology</i> , 2021, , 1.	1.3	3
987	No SARS-CoV-2 reinfection among staff health-care workers: Prospective hospital-wide screening during the first and second waves in Paris. <i>Journal of Clinical Virology</i> , 2021, 145, 104999.	1.6	2
989	Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programmeâ€”The South African Experience. <i>Viruses</i> , 2021, 13, 2050.	1.5	5

#	ARTICLE	IF	CITATIONS
990	Receptor binding domainâ€”IgG levels correlate with protection in residents facing SARSâ€”CoVâ€”2 B.1.1.7 outbreaks. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1885-1894.	2.7	13
992	Hydrogelâ€”Based Slow Release of a Receptorâ€”Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARSâ€”CoVâ€”2. <i>Advanced Materials</i> , 2021, 33, e2104362.	11.1	48
993	Immunogenicity and efficacy of a heterologous ChAdOx1â€”BNT162b2 vaccination. <i>Nature</i> , 2021, 600, 701-706.	13.7	180
994	Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2. <i>Journal of General Virology</i> , 2021, 102, .	1.3	21
995	SARS-CoV-2 Antibody Binding and Neutralization in Dried Blood Spot Eluates and Paired Plasma. <i>Microbiology Spectrum</i> , 2021, 9, e0129821.	1.2	15
996	Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels. <i>Nature Communications</i> , 2021, 12, 6196.	5.8	15
997	Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. <i>Cell Discovery</i> , 2021, 7, 96.	3.1	21
998	Effect of inactivated influenza vaccination on human coronavirus infection: Secondary analysis of a randomized trial in Hutterite colonies. <i>Vaccine</i> , 2021, 39, 7058-7065.	1.7	3
999	Dysregulated Immune Responses in COVID-19 Patients Correlating With Disease Severity and Invasive Oxygen Requirements. <i>Frontiers in Immunology</i> , 2021, 12, 769059.	2.2	16
1000	Recent findings and applications of biomedical engineering for COVID-19 diagnosis: a critical review. <i>Bioengineered</i> , 2021, 12, 8594-8613.	1.4	10
1001	Solutions against emerging infectious and noninfectious human diseases through the application of baculovirus technologies. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 8195-8226.	1.7	18
1002	Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naïve CD8 T cells of unexposed individuals. <i>EBioMedicine</i> , 2021, 72, 103610.	2.7	24
1003	Analysis of IgG, IgA and IgM antibodies against SARSâ€”CoVâ€”2 spike protein S1 in convalescent and vaccinated patients with the Pfizerâ€”BioNTech and CanSinoBio vaccines. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	1.3	9
1004	High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort. <i>The Lancet Global Health</i> , 2021, 9, e1508-e1516.	2.9	10
1006	La respuesta inmune frente a SARS-CoV-2, ¿un arma de doble filo?. <i>Revista De InvestigaciÃ³n Y EducaciÃ³n En Ciencias De La Salud (RIECS)</i> , 2020, 5, 134-142.	0.0	0
1019	An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization. <i>Microbiology Spectrum</i> , 2021, 9, e0105921.	1.2	14
1020	Longitudinal humoral antibody response to SARS-CoV-2 infection among healthcare workers in a New York City hospital. <i>BMJ Open</i> , 2021, 11, e051045.	0.8	6
1021	Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic. <i>Journal of Molecular Biology</i> , 2022, 434, 167332.	2.0	22

#	ARTICLE	IF	CITATIONS
1022	BNT162b2 mRNA vaccine elicited antibody response in blood and milk of breastfeeding women. <i>Nature Communications</i> , 2021, 12, 6222.	5.8	44
1023	Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability. <i>Immunity</i> , 2021, 54, 2908-2921.e6.	6.6	35
1024	Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago. <i>Annals of Epidemiology</i> , 2022, 66, 44-51.	0.9	10
1025	SPEEDS: A portable serological testing platform for rapid electrochemical detection of SARS-CoV-2 antibodies. <i>Biosensors and Bioelectronics</i> , 2022, 197, 113762.	5.3	33
1026	Immunochromatographic test for differentiation detection of IgM and IgG to SARS-CoV-2. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2020, 65, 688-692.	0.2	1
1030	A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies. <i>New Biotechnology</i> , 2022, 66, 46-52.	2.4	5
1031	Electrochemical sensors for the detection of SARS-CoV-2 virus. <i>Chemical Engineering Journal</i> , 2022, 430, 132966.	6.6	115
1033	The MultiBac BEVS: Basics, applications, performance and recent developments. <i>Methods in Enzymology</i> , 2021, 660, 129-154.	0.4	5
1034	Antibody Response to COVID-19 Virus in Heilongjiang Province and Gansu Province, China, 2020. <i>China CDC Weekly</i> , 2020, 2, 645-650.	1.0	0
1035	High Precursor Frequency and Promiscuity in $\hat{\gamma}$ T Cell Receptor Pairing Underpin CD8+ T-Cell Responses to an Immunodominant SARS-CoV-2 Nucleocapsid Epitope. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1036	The Frequency of SARS-CoV-2 Specific Memory B Cells in COVID-19 Recovered Patients Remain Stable While Antibodies Decay Over Time. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1037	Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. <i>Immunity</i> , 2021, 54, 2877-2892.e7.	6.6	260
1038	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. <i>Scientific Reports</i> , 2021, 11, 21601.	1.6	20
1039	The way of SARS-CoV-2 vaccine development: success and challenges. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 387.	7.1	42
1041	Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 31-56.	0.7	8
1042	Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19. <i>Journal of Immunological Methods</i> , 2022, 500, 113182.	0.6	8
1043	SARS-CoV-2 Serology Testing – A Laboratory Primer. <i>Clinics in Laboratory Medicine</i> , 2021, 42, 1-13.	0.7	0
1044	Construction of Optimal SERS Hotspots Based on Capturing the Spike Receptor-Binding Domain (RBD) of SARS-CoV-2 for Highly Sensitive and Specific Detection by a Fish Model. <i>Analytical Chemistry</i> , 2021, 93, 16086-16095.	3.2	22

#	ARTICLE	IF	CITATIONS
1060	Laboratory Tests for COVID-19: A Review of Peer-Reviewed Publications and Implications for Clinical Use. <i>Missouri Medicine</i> , 2020, 117, 184-195.	0.3	17
1061	A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19. <i>Iranian Journal of Medical Sciences</i> , 2021, 46, 151-168.	0.3	2
1062	Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab ϵ) ₂ fragment derived from equine polyclonal antibodies. <i>Toxicology and Applied Pharmacology</i> , 2022, 434, 115796.	1.3	3
1063	Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucum�n, Argentina. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100123.	1.5	21
1064	Overcoming the limitations of COVID-19 diagnostics with nanostructures, nucleic acid engineering, and additive manufacturing. <i>Current Opinion in Solid State and Materials Science</i> , 2022, 26, 100966.	5.6	9
1065	A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. <i>Npj Vaccines</i> , 2021, 6, 143.	2.9	47
1066	Application of SARS-CoV-2 Serology to Address Public Health Priorities. <i>Frontiers in Public Health</i> , 2021, 9, 744535.	1.3	4
1070	Usefulness of ELISA Using Total Antibody against Plant-Expressed Recombinant Nucleocapsid Protein of SARS-CoV-2. <i>Microbiology Spectrum</i> , 2021, , e0067221.	1.2	4
1071	Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern. <i>Cell Reports</i> , 2021, 37, 110114.	2.9	44
1073	Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases. <i>Frontiers in Immunology</i> , 2021, 12, 748291.	2.2	29
1074	Viable Severe Acute Respiratory Syndrome Coronavirus 2 Isolates Exhibit Higher Correlation With Rapid Antigen Assays Than Subgenomic RNA or Genomic RNA. <i>Frontiers in Microbiology</i> , 2021, 12, 718497.	1.5	6
1075	Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers. <i>Immunology</i> , 2022, 165, 250-259.	2.0	21
1076	Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity. <i>Nature Communications</i> , 2021, 12, 6703.	5.8	36
1077	mRNA intramuscular vaccination produces a robust IgG antibody response in advanced neuromuscular disease. <i>Neuromuscular Disorders</i> , 2022, 32, 33-35.	0.3	6
1078	The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries. <i>Viruses</i> , 2021, 13, 2391.	1.5	11
1080	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
1081	Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae <i>Chlamydomonas reinhardtii</i> . <i>PLoS ONE</i> , 2021, 16, e0257089.	1.1	20
1082	The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease. <i>Clinical Science</i> , 2021, 135, 2667-2689.	1.8	97

#	ARTICLE	IF	CITATIONS
1084	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- α inhibitors. <i>Med</i> , 2021, 2, 1327-1341.e4.	2.2	31
1085	Sustained Delivery of SARS-CoV-2 RBD Subunit Vaccine Using a High Affinity Injectable Hydrogel Scaffold. <i>Advanced Healthcare Materials</i> , 2022, 11, e2101714.	3.9	17
1086	Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study. <i>Viruses</i> , 2021, 13, 2270.	1.5	5
1087	Point-of-Care Diagnostic Tools for Surveillance of SARS-CoV-2 Infections. <i>Frontiers in Public Health</i> , 2021, 9, 766871.	1.3	10
1088	Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. <i>Nature Communications</i> , 2021, 12, 6844.	5.8	22
1089	Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. <i>Frontiers in Immunology</i> , 2021, 12, 791764.	2.2	14
1090	Point-of-Care Testingâ€”The Key in the Battle against SARS-CoV-2 Pandemic. <i>Micromachines</i> , 2021, 12, 1464.	1.4	18
1091	SARS-CoV-2 during pregnancy and associated outcomes: Results from an ongoing prospective cohort. <i>Paediatric and Perinatal Epidemiology</i> , 2022, 36, 466-475.	0.8	17
1092	SARS-CoV-2 Antibody Response among Women Infected during Pregnancy. <i>American Journal of Perinatology</i> , 2022, 39, 707-713.	0.6	4
1093	Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka. <i>Frontiers in Public Health</i> , 2021, 9, 724398.	1.3	8
1094	Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins. <i>PLoS ONE</i> , 2021, 16, e0258645.	1.1	13
1095	Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants. <i>Microbiology Spectrum</i> , 2021, 9, e0056021.	1.2	20
1096	The Nuts and Bolts of SARS-CoV-2 Spike Receptor-Binding Domain Heterologous Expression. <i>Biomolecules</i> , 2021, 11, 1812.	1.8	22
1097	Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies. <i>Heliyon</i> , 2021, 7, e08444.	1.4	8
1098	Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes. <i>Vaccines</i> , 2021, 9, 1419.	2.1	4
1099	Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab. <i>Internal Medicine</i> , 2021, 60, 3827-3831.	0.3	8
1100	Rapid test to assess the escape of SARS-CoV-2 variants of concern. <i>Science Advances</i> , 2021, 7, eabl7682.	4.7	21
1101	Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic. <i>RSC Drug Discovery Series</i> , 2021, , 45-60.	0.2	0

#	ARTICLE	IF	CITATIONS
1102	SARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patients. <i>Clinics</i> , 2021, 76, e3548.	0.6	3
1103	Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance. <i>World Journal of Clinical Cases</i> , 2022, 10, 1-11.	0.3	241
1104	All-solid-state SARS-CoV-2 protein biosensor employing colloidal quantum dots-modified electrode. <i>Biosensors and Bioelectronics</i> , 2022, 202, 113974.	5.3	29
1105	ACE2-IgG1 fusions with improved inÂvitro and inÂvivo activity against SARS-CoV-2. <i>IScience</i> , 2022, 25, 103670.	1.9	29
1106	Magnet-assisted electrochemical immunosensor based on surface-clean Pd-Au nanosheets for sensitive detection of SARS-CoV-2 spike protein. <i>Electrochimica Acta</i> , 2022, 404, 139766.	2.6	26
1107	ĐžĐ;ĐžĐ'Đ•Đ'ĐžĐ;ĐĐĐ† Đ†ĐœĐžĐĐ†ĐĐĐ•ĐĐĐž ĐŸĐĐ~ COVID-19. <i>Immunology and Allergy Science and Practice</i> , 2020, ,05-15.		
1108	Inducible protein expression in piggyBac transposase mediated stable HEK293 cell pools. <i>Methods in Enzymology</i> , 2021, 660, 321-339.	0.4	1
1109	Severe acute respiratory syndrome coronavirus-2 IgG antibodies among health-care workers in a tertiary care hospital in Delhi India. <i>Journal of Patient Safety & Infection Control</i> , 2021, 9, 48.	0.1	0
1110	CORONAVIRUS DISEASE (COVID-19). CHALLENGES AND PROSPECTS OF SPECIFIC DIAGNOSTICS. <i>Mikrobiologia I Biotehnologia</i> , 2021, , 6-44.	0.0	0
1111	STRUCTURAL PROTEINS OF THE SARS-COV-2 CORONAVIRUS: ROLE, IMMUNOGENICITY, SUPERANTIGENIC PROPERTIES AND POTENTIAL USE FOR THERAPEUTIC PURPOSES. , 2021, 78, 18-27.		2
1112	A collaborative robotic solution to partly automate SARS-CoV-2 serological tests in small facilities. <i>SLAS Technology</i> , 2022, 27, 100-106.	1.0	4
1113	Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. <i>Nature</i> , 2022, 602, 682-688.	13.7	395
1114	A High-throughput Automated ELISA Assay for Detection of IgG Antibodies to the SARS-CoV-2 Spike Protein. <i>Bio-protocol</i> , 2022, 12, e4301.	0.2	0
1115	Formation and Expansion of Memory B Cells against Coronavirus in Acutely Infected COVID-19 Individuals. <i>Pathogens</i> , 2022, 11, 186.	1.2	4
1117	Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. <i>BMC Medicine</i> , 2022, 20, 26.	2.3	152
1120	An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives. <i>RSC Medicinal Chemistry</i> , 2022, 13, 647-675.	1.7	3
1121	Immune Maturation Effects on Viral Neutralization and Avidity of Hyperimmunized Equine Anti-SARS-CoV-2 Sera. <i>Antibodies</i> , 2022, 11, 3.	1.2	1
1122	Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose. <i>Vaccines</i> , 2022, 10, 153.	2.1	20

#	ARTICLE	IF	CITATIONS
1123	Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. <i>Cell Host and Microbe</i> , 2022, 30, 83-96.e4.	5.1	64
1124	A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection. <i>Science Advances</i> , 2022, 8, eabh3827.	4.7	27
1125	Detection of anti-SARS-CoV-2 antibody for the diagnosis of past-COVID-19 infection cases using a liquid-crystal-based immunosensor. <i>Liquid Crystals</i> , 2022, 49, 1285-1296.	0.9	4
1126	Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naïve patients. <i>Blood Cancer Journal</i> , 2022, 12, 8.	2.8	5
1127	Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations. <i>Journal of Clinical Virology</i> , 2022, 146, 105061.	1.6	14
1128	Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. <i>EBioMedicine</i> , 2022, 75, 103805.	2.7	60
1131	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. <i>Cell Reports Medicine</i> , 2022, 3, 100528.	3.3	6
1132	Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges. <i>Nature Communications</i> , 2022, 13, 140.	5.8	22
1133	Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition. <i>Frontiers in Immunology</i> , 2022, 13, 830710.	2.2	19
1134	Immunoglobulin-G antibodies against severe acute respiratory syndrome “ coronavirus-2 among health-care workers: A serosurveillance study from India. <i>International Journal of Applied & Basic Medical Research</i> , 2022, 12, 18.	0.2	1
1135	SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. <i>PLoS ONE</i> , 2022, 17, e0262169.	1.1	29
1136	Structural insights in cell-type specific evolution of intra-host diversity by SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, 222.	5.8	23
1137	Construction of SARS-CoV-2 virus-like particles in plant. <i>Scientific Reports</i> , 2022, 12, 1005.	1.6	26
1138	SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study. <i>Vaccine</i> , 2022, 40, 206-212.	1.7	20
1139	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. <i>Journal of Biomedical Science</i> , 2022, 29, 1.	2.6	144
1140	IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma Pools. <i>PLoS ONE</i> , 2022, 17, e0262162.	1.1	23
1141	Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, 405.	5.8	92
1143	Vaccination Induces Stronger Spike Immunity and Better Protection Against SARS-CoV-2 Infection in COVID-19 Recovered Subjects than in Naïve Individuals. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1144	Innovative FO-SPR Label-free Strategy for Detecting Anti-RBD Antibodies in COVID-19 Patient Serum and Whole Blood. <i>ACS Sensors</i> , 2022, 7, 477-487.	4.0	31
1145	Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. <i>Cell</i> , 2022, 185, 1008-1024.e15.	13.5	101
1146	A quantitative assay for detection of SARS-CoV-2 neutralizing antibodies. <i>Journal of Clinical Virology</i> , 2022, 147, 105064.	1.6	6
1147	Designed SARS-CoV-2 receptor binding domain variants form stable monomers. <i>Biotechnology Journal</i> , 2022, 17, e2100422.	1.8	8
1148	Immunity to SARS-CoV-2 up to 15 months after infection. <i>IScience</i> , 2022, 25, 103743.	1.9	56
1150	SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020–March 2021. <i>Emerging Infectious Diseases</i> , 2022, 28, 556-563.	2.0	6
1151	Zinc associated nanomaterials and their intervention in emerging respiratory viruses: Journey to the field of biomedicine and biomaterials. <i>Coordination Chemistry Reviews</i> , 2022, 457, 214402.	9.5	28
1152	Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 248-256.	0.6	13
1154	Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence. <i>Frontiers in Immunology</i> , 2022, 13, 796481.	2.2	7
1155	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. <i>Cell</i> , 2022, 185, 896-915.e19.	13.5	189
1156	Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals. <i>Viruses</i> , 2022, 14, 370.	1.5	5
1158	Thermally Responsive Alkane Partitions for Assay Automation. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 8865-8875.	4.0	1
1159	Expression, purification and characterization of SARS-CoV-2 spike RBD in ExpiCHO cells. <i>Protein Expression and Purification</i> , 2022, 194, 106071.	0.6	11
1160	<i>Streptococcus pneumoniae</i> colonization associates with impaired adaptive immune responses against SARS-CoV-2. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	33
1161	The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin $\alpha 5 \beta 1$ and NF- κ B signaling. <i>Journal of Biological Chemistry</i> , 2022, 298, 101695.	1.6	74
1162	Analytical characterization of the SARS-CoV-2 EURM-017 reference material. <i>Clinical Biochemistry</i> , 2022, 101, 19-25.	0.8	5
1163	Isothermal gene amplification coupled MALDI-TOF MS for SARS-CoV-2 detection. <i>Talanta</i> , 2022, 242, 123297.	2.9	12
1164	Next-Generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire. <i>Journal of Proteome Research</i> , 2022, 21, 274-288.	1.8	16

#	ARTICLE	IF	CITATIONS
1165	Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. <i>Nature</i> , 0, , .	13.7	56
1169	Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants. <i>MBio</i> , 2021, 12, e0265621.	1.8	14
1170	Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor. <i>ELife</i> , 2021, 10, .	2.8	29
1171	Serum Cytokine Profiles of Rapid Recovery Patients with COVID-19: Series of 6 Cases. <i>Kobe Journal of Medical Sciences</i> , 2021, 67, E55-E60.	0.2	0
1172	A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination. <i>Clinical and Translational Immunology</i> , 2022, 11, e1380.	1.7	65
1175	mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. <i>Scientific Reports</i> , 2022, 12, 2628.	1.6	34
1176	Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients. <i>PLoS ONE</i> , 2022, 17, e0261979.	1.1	10
1177	Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). <i>Scientific Reports</i> , 2022, 12, 2552.	1.6	23
1179	Low-entry-barrier point-of-care testing of anti-SARS-CoV-2 IgG in the population of Upper Austria from December 2020 until April 2021—a feasible surveillance strategy for post-pandemic monitoring?. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 3291-3299.	1.9	0
1180	Anti-RBD IgA and IgG Response and Transmission in Breast Milk of Anti-SARS-CoV-2 Vaccinated Mothers. <i>Pathogens</i> , 2022, 11, 286.	1.2	14
1181	COVID-19 mRNA vaccines: Platforms and current developments. <i>Molecular Therapy</i> , 2022, 30, 1850-1868.	3.7	102
1182	Comparative Investigation of Methods for Analysis of SARS-CoV-2-Spike-Specific Antisera. <i>Viruses</i> , 2022, 14, 410.	1.5	3
1184	Enzyme-Linked Immunosorbent Assay: An Adaptable Methodology to Study SARS-CoV-2 Humoral and Cellular Immune Responses. <i>Journal of Clinical Medicine</i> , 2022, 11, 1503.	1.0	4
1185	Comparison of Seroconversion in Children and Adults With Mild COVID-19. <i>JAMA Network Open</i> , 2022, 5, e221313.	2.8	55
1186	Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. <i>Wellcome Open Research</i> , 0, 6, 220.	0.9	1
1187	A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 103960.	1.9	16
1188	Possible Cross-Reactivity of Feline and White-Tailed Deer Antibodies against the SARS-CoV-2 Receptor Binding Domain. <i>Journal of Virology</i> , 2022, 96, e0025022.	1.5	10
1189	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	13.7	117

#	ARTICLE	IF	CITATIONS
1191	Sensitive and specific serological ELISA for the detection of SARS-CoV-2 infections. <i>Virology Journal</i> , 2022, 19, 50.	1.4	15
1192	Nanoplasmonic multiplex biosensing for COVID-19 vaccines. <i>Biosensors and Bioelectronics</i> , 2022, 208, 114193.	5.3	10
1193	Microfluidic Antibody Affinity Profiling Reveals the Role of Memory Reactivation and Cross-Reactivity in the Defense Against SARS-CoV-2. <i>ACS Infectious Diseases</i> , 2022, 8, 790-799.	1.8	8
1194	A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs. <i>Viruses</i> , 2022, 14, 562.	1.5	2
1197	Prevalence of anti-severe acute respiratory syndrome coronavirus 2 antibodies in cats in Germany and other European countries in the early phase of the coronavirus disease-19 pandemic. <i>Zoonoses and Public Health</i> , 2022, 69, 439-450.	0.9	12
1199	A serological investigation in Southern Italy: was SARS-CoV-2 circulating in late 2019?. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-9.	1.4	5
1200	Hydrophobic Localized Enrichment of Co-reactants to Enhance Electrochemiluminescence of Conjugated Polymers for Detecting SARS-CoV-2 Nucleocapsid Proteins. <i>Analytical Chemistry</i> , 2022, 94, 4446-4454.	3.2	15
1202	Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 62, 103737.	0.9	13
1203	Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2977.	1.8	4
1204	Induction of broadly reactive influenza antibodies increases susceptibility to autoimmunity. <i>Cell Reports</i> , 2022, 38, 110482.	2.9	7
1205	De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. <i>Nature Communications</i> , 2022, 13, 1547.	5.8	159
1206	A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies. <i>Vaccine</i> , 2022, 40, 1958-1967.	1.7	5
1208	Antibody Response to SARS-CoV-2 in Relation to the Contributing Factors in COVID-19 Patients. <i>Viral Immunology</i> , 2022, 35, 142-149.	0.6	3
1209	An Analysis of Serological Response and Infection Outcomes Following Oxford-AstraZeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2) SARS-CoV-2 Vaccines in Kidney and Kidney-pancreas Transplants. <i>Transplantation</i> , 2022, 106, 1421-1429.	0.5	7
1210	Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida. <i>JAMA Oncology</i> , 2022, 8, 748.	3.4	20
1211	Advances in purification of SARS-CoV-2 spike ectodomain protein using high-throughput screening and non-affinity methods. <i>Scientific Reports</i> , 2022, 12, 4458.	1.6	4
1212	Multiplexed COVID-19 antibody quantification from human sera using label-free nanoplasmonic biosensors. <i>Biomedical Optics Express</i> , 2022, 13, 2130.	1.5	10
1213	Low Levels of Neutralizing Antibodies After Natural Infection With Severe Acute Respiratory Syndrome Coronavirus 2 in a Community-Based Serological Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac055.	0.4	4

#	ARTICLE	IF	CITATIONS
1217	A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines. <i>Vaccine</i> , 2022, 40, 2551-2560.	1.7	11
1218	Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds. <i>GeroScience</i> , 2022, 44, 1229-1240.	2.1	10
1219	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. <i>Communications Medicine</i> , 2022, 2, .	1.9	3
1223	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. <i>Immunity</i> , 2022, 55, 998-1012.e8.	6.6	86
1225	Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals. <i>EBioMedicine</i> , 2022, 78, 103972.	2.7	31
1226	BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?. <i>EMBO Molecular Medicine</i> , 2022, 14, e15326.	3.3	30
1227	SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. <i>Nature Immunology</i> , 2022, 23, 781-790.	7.0	116
1228	A Cell-Free Assay for Rapid Screening of Inhibitors of hACE2-Receptor SARS-CoV-2-Spike Binding. <i>ACS Synthetic Biology</i> , 2022, 11, 1389-1396.	1.9	0
1229	Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak. <i>PLoS ONE</i> , 2022, 17, e0266270.	1.1	11
1230	Intranasal delivery of SARS-CoV-2 spike protein is sufficient to cause olfactory damage, inflammation and olfactory dysfunction in zebrafish. <i>Brain, Behavior, and Immunity</i> , 2022, 102, 341-359.	2.0	27
1231	The immunologic response to severe acute respiratory syndrome coronavirus 2. <i>Allergy and Asthma Proceedings</i> , 2021, 42, 495-505.	1.0	5
1232	Functional Trimeric SARS-CoV-2 Envelope Protein Expressed in Stable CHO Cells. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 779359.	2.0	4
1233	Coronavirus Disease 2019 (COVID-19): Emerging detection technologies and auxiliary analysis. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24152.	0.9	10
1234	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. <i>Frontiers in Pharmacology</i> , 2021, 12, 778219.	1.6	0
1235	Effects of Influenza Vaccination on the Response to BNT162b2 Messenger RNA COVID-19 Vaccine in Healthcare Workers. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 549-555.	0.6	8
1237	Plasmonic Metasurfaces for Medical Diagnosis Applications: A Review. <i>Sensors</i> , 2022, 22, 133.	2.1	23
1240	No neutralizing effect of pre-existing tick-borne encephalitis virus antibodies against severe acute respiratory syndrome coronavirus-2: a prospective healthcare worker study. <i>Scientific Reports</i> , 2021, 11, 24198.	1.6	0
1241	Current aspects of COVID-19 vaccine prophylaxis: big steps from laboratory to clinical practice. <i>Problemy Zdravĕnia i Ākologii</i> , 2021, 18, 5-16.	0.0	0

#	ARTICLE	IF	CITATIONS
1242	Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals. <i>Frontiers in Immunology</i> , 2021, 12, 759688.	2.2	29
1244	Host Predictors of Broadly Cross-Reactive Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern Differ Between Infection and Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 75, e705-e714.	2.9	10
1245	Highly Sensitive and Specific SARS-CoV-2 Serological Assay Using a Magnetic Modulation Biosensing System. <i>Biosensors</i> , 2022, 12, 7.	2.3	3
1246	Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses. <i>Cell Reports</i> , 2021, 37, 110169.	2.9	34
1248	Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. <i>PLoS Biology</i> , 2021, 19, e3001384.	2.6	15
1249	Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison. <i>PLoS ONE</i> , 2021, 16, e0261003.	1.1	24
1250	High-Yield Production of Receptor Binding Domain of SARS-CoV-2 Linked to Bacterial Flagellin in Plants Using Self-Replicating Viral Vector pEff. <i>Plants</i> , 2021, 10, 2682.	1.6	10
1251	Modeling serological testing to inform relaxation of social distancing for COVID-19 control. <i>Nature Communications</i> , 2021, 12, 7063.	5.8	11
1252	An Integrated Platform for Serological Detection and Vaccination of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 771011.	2.2	6
1255	Insect Cells for High-Yield Production of SARS-CoV-2 Spike Protein: Building a Virosome-Based COVID-19 Vaccine Candidate. <i>Pharmaceutics</i> , 2022, 14, 854.	2.0	8
1256	Deciphering the quality of SARS-CoV-2 specific T cell response associated with disease severity, immune memory and heterologous response. <i>Clinical and Translational Medicine</i> , 2022, 12, e802.	1.7	8
1257	mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2. <i>Med</i> , 2022, 3, 309-324.e6.	2.2	6
1258	Potential importance of early treatment of SARS-CoV-2 infection in intestinal transplant patient: A case report. <i>World Journal of Transplantation</i> , 2022, 12, 72-78.	0.6	0
1260	A Highly Potent SARS-CoV-2 Blocking Lectin Protein. <i>ACS Infectious Diseases</i> , 2022, 8, 1253-1264.	1.8	20
1262	Embedding Proteins within Spatially Controlled Hierarchical Nanoarchitectures for Ultrasensitive Immunoassay. <i>Analytical Chemistry</i> , 2022, 94, 6271-6280.	3.2	6
1263	Chemically Modified Bacterial Sacculi as a Vaccine Microparticle Scaffold. <i>ACS Chemical Biology</i> , 2022, 17, 1184-1196.	1.6	5
1265	Transient Expression of Glycosylated SARS-CoV-2 Antigens in <i>Nicotiana benthamiana</i> . <i>Plants</i> , 2022, 11, 1093.	1.6	12
1266	Assessment of specific human antibodies against SARS-CoV-2 receptor binding domain by rapid in-house ELISA. <i>Human Antibodies</i> , 2022, 30, 105-115.	0.6	5

#	ARTICLE	IF	CITATIONS
1274	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. <i>Nature</i> , 2022, 607, 128-134.	13.7	197
1275	Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain. <i>MBio</i> , 2022, 13, e0358021.	1.8	12
1276	Anti-SARS-CoV-2 IgG antibodies induced by the BNT162b2 mRNA vaccine is age-dependent and influenced by a previous natural SARS-CoV-2 infection.. <i>Acta Biomedica</i> , 2022, 92, e2021464.	0.2	0
1277	Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 487.	2.1	4
1278	Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients. <i>Frontiers in Immunology</i> , 2022, 13, 878812.	2.2	3
1279	Features of humoral immunity after COVID-19. <i>Medical Immunology (Russia)</i> , 2022, 24, 337-350.	0.1	2
1280	Gold Nanoparticle-Mediated Lateral Flow Assays for Detection of Host Antibodies and COVID-19 Proteins. <i>Nanomaterials</i> , 2022, 12, 1456.	1.9	17
1281	Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 895209.	2.2	13
1282	Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac. <i>Vaccine</i> , 2022, 40, 3320-3329.	1.7	6
1284	COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants. <i>Scientific Reports</i> , 2022, 12, 7168.	1.6	15
1285	Detecting anti-SARS-CoV-2 antibodies in urine samples: A noninvasive and sensitive way to assay COVID-19 immune conversion. <i>Science Advances</i> , 2022, 8, eabn7424.	4.7	14
1286	Rapid Generation of In-House Serological Assays Is Comparable to Commercial Kits Critical for Early Response to Pandemics: A Case With SARS-CoV-2. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	3
1288	Equipment-free, gold nanoparticle based semiquantitative assay of SARS-CoV-2-S1RBD IgG from fingertip blood: A practical strategy for on-site measurement of COVID-19 antibodies. <i>Talanta</i> , 2022, 246, 123498.	2.9	3
1289	Measuring Neutralizing Antibodies to SARS-CoV-2 Using Lentiviral Spike-Pseudoviruses. <i>Methods in Molecular Biology</i> , 2022, 2452, 305-314.	0.4	2
1290	SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T _H cell responses more efficiently than other variants in mild COVID-19 convalescents. <i>Cell Reports Medicine</i> , 2022, 3, 100651.	3.3	24
1291	A self-pressure-driven blood plasma-separation device for point-of-care diagnostics. <i>Talanta</i> , 2022, 247, 123562.	2.9	4
1292	SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity. <i>Nature Communications</i> , 2022, 13, 2774.	5.8	21
1293	PARIS and SPARTA: Finding the Achilles'™ Heel of SARS-CoV-2. <i>MSphere</i> , 2022, 7, e0017922.	1.3	25

#	ARTICLE	IF	CITATIONS
1294	SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. <i>ELife</i> , 2022, 11, .	2.8	34
1297	German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance. <i>Communications Medicine</i> , 2022, 2, .	1.9	6
1299	Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan. <i>Vaccines</i> , 2022, 10, 830.	2.1	5
1300	Persistence of Anti SARS-CoV-2 Antibodies in Breast Milk from Infected and Vaccinated Women after In Vitro-Simulated Gastrointestinal Digestion. <i>Nutrients</i> , 2022, 14, 2117.	1.7	6
1301	SARS-CoV-2 accessory proteins reveal distinct serological signatures in children. <i>Nature Communications</i> , 2022, 13, .	5.8	22
1302	Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease. <i>Npj Vaccines</i> , 2022, 7, .	2.9	8
1303	COVID-19 Diagnostics: A Panoramic View on Its Present Scenario, Challenges and Solutions. <i>Proceedings of the National Academy of Sciences India Section B - Biological Sciences</i> , 0, , .	0.4	2
1304	Development of Ethical COVID-19 Antibody Testing that Adheres to Pro-Life Principles. <i>Linacre quarterly, The</i> , 0, , 002436392210959.	0.1	0
1305	Evaluation of a photoelectrochemical platform based on strontium titanate, sulfur doped carbon nitride and palladium nanoparticles for detection of SARS-CoV-2 spike glycoprotein S1. <i>Biosensors and Bioelectronics: X</i> , 2022, 11, 100167.	0.9	4
1306	Sensitive methods for detection of SARS-CoV-2 RNA. <i>Methods in Microbiology</i> , 2022, , 1-26.	0.4	2
1307	SARS-CoV-2 infection in patients with inborn errors of immunity due to DNA repair defects. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, , .	0.9	3
1308	No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination. <i>PLoS Biology</i> , 2022, 20, e3001506.	2.6	10
1309	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. <i>JCI Insight</i> , 2022, 7, .	2.3	24
1311	The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination. <i>Vaccines</i> , 2022, 10, 794.	2.1	5
1312	SARS-CoV-2 RBD-specific and NP-specific antibody response of healthcare workers in the westernmost Austrian state Vorarlberg: a prospective cohort study. <i>BMJ Open</i> , 2022, 12, e052130.	0.8	2
1313	Principles of SARS-CoV-2 glycosylation. <i>Current Opinion in Structural Biology</i> , 2022, 75, 102402.	2.6	27
1314	A Universal Fluorescent Immunochromatography Assay Based on Quantum Dot Nanoparticles for the Rapid Detection of Specific Antibodies against SARS-CoV-2 Nucleocapsid Protein. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6225.	1.8	6
1315	Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months. <i>PLoS Pathogens</i> , 2022, 18, e1010569.	2.1	6

#	ARTICLE	IF	CITATIONS
1316	Production of novel SARS-CoV-2 Spike truncations in Chinese hamster ovary cells leads to high expression and binding to antibodies. <i>Biotechnology Journal</i> , 0, , 2100678.	1.8	2
1317	SERS-based assay for multiplexed detection of cross-reactivity and persistence of antibodies against the spike of the native, P.1 and B.1.617.2 SARS-CoV-2 in non-hospitalised adults. <i>Sensors & Diagnostics</i> , 2022, 1, 851-866.	1.9	3
1318	An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1319	Near-Infrared-Emissive AIE Bioconjugates: Recent Advances and Perspectives. <i>Molecules</i> , 2022, 27, 3914.	1.7	8
1321	Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. <i>Wellcome Open Research</i> , 0, 6, 220.	0.9	4
1322	Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. , 2022, 10, e004766.		11
1323	SARS-CoV-2-specific T cell memory with common TCRÎ±Î² motifs is established in unvaccinated children who seroconvert after infection. <i>Immunity</i> , 2022, 55, 1299-1315.e4.	6.6	23
1324	Blood and saliva SARS-CoV-2 antibody levels in self-collected dried spot samples. <i>Medical Microbiology and Immunology</i> , 2022, 211, 173-183.	2.6	5
1325	Inhibitors of Activin Receptor-like Kinase 5 Interfere with SARS-CoV-2 S-Protein Processing and Spike-Mediated Cell Fusion via Attenuation of Furin Expression. <i>Viruses</i> , 2022, 14, 1308.	1.5	1
1327	The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization. <i>MSphere</i> , 2022, 7, .	1.3	16
1329	Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. <i>BMC Medicine</i> , 2022, 20, .	2.3	13
1330	An updated review of <sc>SARS-CoV-2</sc> detection methods in the context of a novel coronavirus pandemic. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	19
1331	A diminished immune response underlies age-related SARS-CoV-2 pathologies. <i>Cell Reports</i> , 2022, 39, 111002.	2.9	20
1332	Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	14
1333	A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222. <i>Vaccines</i> , 2022, 10, 914.	2.1	3
1334	SARS-CoV-2 antibody response after BNT162b2 mRNA vaccine in healthcare workers: Nine-month of follow-up. <i>Vaccine: X</i> , 2022, 11, 100175.	0.9	5
1335	Validation of laboratory developed serology assays for detection of IgG antibody to severe acute respiratory syndrome coronavirus 2 in the South African population. <i>Journal of Virological Methods</i> , 2022, 307, 114571.	1.0	2
1336	An impedimetric biosensor for COVID-19 serology test and modification of sensor performance via dielectrophoresis force. <i>Biosensors and Bioelectronics</i> , 2022, 213, 114476.	5.3	20

#	ARTICLE	IF	CITATIONS
1337	Robust humoral immune response after boosting in children with Multisystem Inflammatory Syndrome in Children. <i>IDCases</i> , 2022, 29, e01569.	0.4	1
1338	Landscape Determinants of Infectivity and Insights into Vaccine Development and Effectiveness - Novel Coronavirus. <i>Letters in Drug Design and Discovery</i> , 2023, 20, 119-143.	0.4	1
1339	Differential Dynamics of Humoral and Cell-Mediated Immunity with Three Doses of BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers in Japan: A Prospective Cohort Study. <i>Vaccines</i> , 2022, 10, 1050.	2.1	3
1340	Association of SARS-CoV-2 Seropositivity and Symptomatic Reinfection in Children in Nicaragua. <i>JAMA Network Open</i> , 2022, 5, e2218794.	2.8	8
1341	Antibody-Î Invertase Fusion Protein Enables Quantitative Detection of SARS-CoV-2 Antibodies Using Widely Available Glucometers. <i>Journal of the American Chemical Society</i> , 2022, 144, 11226-11237.	6.6	13
1342	Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital. <i>Vaccines</i> , 2022, 10, 1031.	2.1	6
1343	Tissue immunity to SARS-CoV-2: Role in protection and immunopathology*. <i>Immunological Reviews</i> , 2022, 309, 25-39.	2.8	11
1344	An RBD-Based Diagnostic Method Useful for the Surveillance of Protective Immunity against SARS-CoV-2 in the Population. <i>Diagnostics</i> , 2022, 12, 1629.	1.3	5
1345	Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents. <i>Vaccines</i> , 2022, 10, 1098.	2.1	4
1346	Clinical and Serological Findings of COVID-19 Participants in the Region of Makkah, Saudi Arabia. <i>Diagnostics</i> , 2022, 12, 1725.	1.3	0
1347	Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines. <i>IScience</i> , 2022, 25, 104739.	1.9	4
1348	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	10
1349	From a recombinant key antigen to an accurate, affordable serological test: Lessons learnt from COVID-19 for future pandemics. <i>Biochemical Engineering Journal</i> , 2022, 186, 108537.	1.8	22
1351	Guardians of the oral and nasopharyngeal galaxy: <sc>IgA</sc> and protection against <sc>SARS-CoV</sc>-2 infection*. <i>Immunological Reviews</i> , 2022, 309, 75-85.	2.8	32
1352	Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 98.	1.5	5
1353	Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104766.	1.9	13
1354	Directly immersible silicon photonic probes: Application to rapid SARS-CoV-2 serological testing. <i>Biosensors and Bioelectronics</i> , 2022, 215, 114570.	5.3	8
1355	GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2. <i>Pathogens</i> , 2022, 11, 806.	1.2	3

#	ARTICLE	IF	CITATIONS
1356	Proof-of-concept for speedy development of rapid and simple at-home method for potential diagnosis of early COVID-19 mutant infections using nanogold and aptamer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 45, 102590.	1.7	3
1357	Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput, Serological Studies of SARS-CoV-2. <i>ACS Infectious Diseases</i> , 2022, 8, 1468-1479.	1.8	4
1358	Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview. <i>Journal of Diabetes and Metabolic Disorders</i> , 2022, 21, 1763-1783.	0.8	4
1359	Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1360	Kinetics of anti-SARS-CoV-2 responses post complete vaccination with coronavac: A prospective study in 50 health workers. <i>Journal of Public Health Research</i> , 2022, 11, 227990362211041.	0.5	1
1361	Understanding the Excitation Wavelength Dependence and Thermal Stability of the SARS-CoV-2 Receptor-Binding Domain Using Surface-Enhanced Raman Scattering and Machine Learning. <i>ACS Photonics</i> , 2022, 9, 2963-2972.	3.2	10
1363	SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients – a comparative long term post-infection study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1364	De novo emergence of SARS-CoV-2 spike mutations in immunosuppressed patients. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	9
1367	A Rapid and Sensitive Microfluidics-Based Tool for Seroprevalence Immunity Assessment of COVID-19 and Vaccination-Induced Humoral Antibody Response at the Point of Care. <i>Biosensors</i> , 2022, 12, 621.	2.3	7
1368	Engineered multivalent self-assembled binder protein against SARS-CoV-2 RBD. <i>Biochemical Engineering Journal</i> , 2022, 187, 108596.	1.8	2
1369	Development and validation of an enzyme-linked immunoassay kit for diagnosis and surveillance of COVID-19. <i>Journal of Clinical Virology Plus</i> , 2022, 2, 100101.	0.4	5
1370	Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology. <i>Vaccine</i> , 2022, 40, 5892-5903.	1.7	6
1371	SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants. <i>MBio</i> , 2022, 13, .	1.8	6
1372	Diagnostic Performance of Three ELISAs for Detection of Antibodies against SARS-CoV-2 in Human Samples. <i>Scientific World Journal, The</i> , 2022, 2022, 1-7.	0.8	2
1373	Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer. <i>Cell Reports Methods</i> , 2022, 2, 100273.	1.4	5
1374	Integration of Multiple Interferometers in Highly Multiplexed Diagnostic KITs to Evaluate Several Biomarkers of COVID-19 in Serum. <i>Biosensors</i> , 2022, 12, 671.	2.3	2
1376	Recent Advances in CRISPR-Based Biosensors for Point-of-Care Pathogen Detection. <i>CRISPR Journal</i> , 2022, 5, 500-516.	1.4	14
1377	IgG antibodies to SARS-CoV-2 in asymptomatic blood donors at two time points in Karachi. <i>PLoS ONE</i> , 2022, 17, e0271259.	1.1	6

#	ARTICLE	IF	CITATIONS
1378	Serum N-glycomic profiling may provide potential signatures for surveillance of COVID-19. <i>Glycobiology</i> , 0, , .	1.3	1
1379	Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	12
1380	A lab-on-a-chip for the concurrent electrochemical detection of SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies in saliva and plasma. <i>Nature Biomedical Engineering</i> , 2022, 6, 968-978.	11.6	109
1381	Development of robust, indigenous ELISA for detection of IgG antibodies against CoV-2ÂN and S proteins: mass screening. <i>Applied Microbiology and Biotechnology</i> , 0, , .	1.7	2
1382	The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development. <i>Vaccines</i> , 2022, 10, 1346.	2.1	4
1383	SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021. <i>PLOS Global Public Health</i> , 2022, 2, e0000883.	0.5	5
1384	Ultrarapid and ultrasensitive detection of SARSâCoVâ2 antibodies in COVIDâ19 patients via a 3Dâprinted nanomaterialâbased biosensing platform. <i>Journal of Medical Virology</i> , 2022, 94, 5808-5826.	2.5	8
1386	Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged people. <i>JCI Insight</i> , 2022, 7, .	2.3	10
1387	DEVELOPMENT AND VALIDATION OF AN ENZYME-LINKED IMMUNOASSAY KIT FOR DIAGNOSIS AND SURVEILLANCE OF COVID-19. <i>Journal of Clinical Virology Plus</i> , 2022, , 100103.	0.4	0
1388	Follow-up study of anti-SARS-CoV-2 IgG antibody response in COVID-19 patients up to 6 months after infection. <i>Future Microbiology</i> , 2022, 17, 1043-1049.	1.0	0
1389	Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study. <i>EBioMedicine</i> , 2022, 83, 104208.	2.7	29
1391	Fluorescent nanodiamond-based spin-enhanced lateral flow immunoassay for detection of SARS-CoV-2 nucleocapsid protein and spike protein from different variants. <i>Analytica Chimica Acta</i> , 2022, 1230, 340389.	2.6	20
1392	Oral inhalation of cannabidiol delivered from a metered dose inhaler to alleviate cytokine production induced by SARS-CoV-2 and pollutants. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103805.	1.4	2
1393	Humoral cross-coronavirus responses against the S2 region in children with Kawasaki disease. <i>Virology</i> , 2022, 575, 83-90.	1.1	1
1394	Dynamics of SARS-CoV-2 exposure in Malawian infants between February 2020 and May 2021. <i>Journal of Clinical Virology Plus</i> , 2022, 2, 100110.	0.4	1
1395	Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents. <i>Vaccine: X</i> , 2022, 12, 100211.	0.9	4
1396	Reliable estimation of SARS-CoV-2 anti-spike protein IgG titers from single dilution optical density values in serologic surveys. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 104, 115807.	0.8	0
1397	A Pilot Study: Validation of Dried Blood Spots (DBS) to Assess SARS-CoV2 IgG Antibody Immunoassays in Hispanic Pregnant Women. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1398	Current clinical testing approach of COVID. , 2022, , 231-274.		0
1399	Nanotechnology-based bio-tools and techniques for COVID-19 management. , 2022, , 127-148.		0
1400	Biophysical and structural characterizations of the effects of mutations on the structureâ€“activity relationships of SARS-CoV-2 spike protein. <i>Methods in Enzymology</i> , 2022, , 299-321.	0.4	2
1401	Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9763.	1.8	17
1402	A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo. <i>Cell Reports Medicine</i> , 2022, 3, 100774.	3.3	14
1403	Utilization of Receptor-Binding Domain of SARS-CoV-2 Spike Protein Expressed in <i>Escherichia coli</i> for the Development of Neutralizing Antibody Assay. <i>Molecular Biotechnology</i> , 0, , .	1.3	2
1404	Deep immunophenotyping reveals biomarkers of multisystemic inflammatory syndrome in children in a Latin American cohort. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 1074-1085.e11.	1.5	9
1405	Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	37
1406	COVID-19 Serosurvey of Frontline Healthcare Workers in Western Australia. <i>Journal of Epidemiology and Global Health</i> , 2022, 12, 472-477.	1.1	1
1407	Rational Design and Development of SARS-CoV-2 Serological Diagnostics by Immunoprecipitation-Targeted Proteomics. <i>Analytical Chemistry</i> , 2022, 94, 12990-12999.	3.2	8
1409	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1410	<i>Mamestra brassicae</i> NIAS-Mb-32 cell strain 2g2 enables high-yield recombinant protein production in baculovirus-free and baculovirus-based insect cell expression. <i>Journal of Bioscience and Bioengineering</i> , 2022, 134, 432-440.	1.1	1
1411	Sensitive Serology Measurements in the Saliva of Individuals with COVID-19 Symptoms Using a Multiplexed Immunoassay. <i>Journal of Applied Laboratory Medicine</i> , The, 0, , .	0.6	0
1412	Durability of S-RBD IgG Antibody Levels after Sinovac Vaccination in Healthcare Workers. <i>Folia Medica Indonesiana</i> , 2022, 58, 234-241.	0.1	0
1413	Circulating multimeric immune complexes contribute to immunopathology in COVID-19. <i>Nature Communications</i> , 2022, 13, .	5.8	13
1415	Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2. <i>Vaccine</i> , 2022, 40, 5868-5872.	1.7	3
1416	SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals. <i>Nature Communications</i> , 2022, 13, .	5.8	74
1417	Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern. <i>IScience</i> , 2022, 25, 105193.	1.9	7

#	ARTICLE	IF	CITATIONS
1419	mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. <i>Vaccine</i> , 2022, 40, 6114-6124.	1.7	37
1420	Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD [®] , Φ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
1421	Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster. <i>Vaccine: X</i> , 2022, 12, 100221.	0.9	2
1422	Novel reverse transcription-multiple inner primer loop-mediated isothermal amplification (RT-MIPLAMP) for visual and sensitive detection of SARS-CoV-2. <i>Analytical Methods</i> , 2022, 14, 5012-5018.	1.3	5
1423	Current strategy of SARS-CoV-2 molecular detection. <i>Analytical Methods</i> , 0, , .	1.3	0
1424	Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents. <i>Vaccines</i> , 2022, 10, 1646.	2.1	4
1425	SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations. <i>Cell Reports</i> , 2022, 41, 111496.	2.9	20
1426	A combined fine needle aspiration and spectral flow cytometry approach to assess human germinal center responses to SARS-CoV-2 vaccination. <i>STAR Protocols</i> , 2022, 3, 101840.	0.5	3
1427	Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. <i>Science</i> , 2022, 378, .	6.0	141
1428	Optimizing the implementation of a participant-collected, mail-based SARS-CoV-2 serological survey in university-affiliated populations: lessons learned and practical guidance. <i>BMC Public Health</i> , 2022, 22, .	1.2	0
1429	A Rapid SARS-CoV-2 Nucleocapsid Protein Profiling Assay with High Sensitivity Comparable to Nucleic Acid Detection. <i>Analytical Chemistry</i> , 2022, 94, 14627-14634.	3.2	9
1430	Pandemic [™] 's silver lining. <i>MAbs</i> , 2022, 14, .	2.6	1
1431	Comparison of nucleocapsid and spike antibody ELISAs for determining SARS [®] CoV [®] 2 seropositivity in Kenyan women and infants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	2
1432	Nucleic Acid Vaccines against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 1849.	2.1	10
1433	The Performances of Three Commercially Available Assays for the Detection of SARS-CoV-2 Antibodies at Different Time Points Following SARS-CoV-2 Infection. <i>Viruses</i> , 2022, 14, 2196.	1.5	0
1434	Simultaneous Rapid Nucleic Acid and Protein Detection in a Lateral Chromatography Chip for COVID-19 Diagnosis. <i>ACS Omega</i> , 2022, 7, 38409-38416.	1.6	1
1435	Serological response after anti-SARS-CoV-2 BNT162b2 vaccine in IBD patients on biological therapy: a monocentric case-control study. <i>Minerva Gastroenterology</i> , 0, , .	0.3	0
1437	Comparable diagnostic accuracy of SARS-CoV-2 Spike RBD and N-specific IgG tests to determine pre-vaccination nation-wide baseline seroprevalence in Mexico. <i>Scientific Reports</i> , 2022, 12, .	1.6	3

#	ARTICLE	IF	CITATIONS
1439	Ultrafast one-minute electronic detection of SARS-CoV-2 infection by 3CLpro enzymatic activity in untreated saliva samples. <i>Nature Communications</i> , 2022, 13, .	5.8	15
1440	Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1441	Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020â€“21. <i>PLoS ONE</i> , 2022, 17, e0265478.	1.1	9
1442	Production of the SARS-CoV-2 Spike protein and its Receptor Binding Domain in plant cell suspension cultures. <i>Frontiers in Plant Science</i> , 0, 13, .	1.7	6
1443	Development of mRNA vaccines against respiratory syncytial virus (RSV). <i>Cytokine and Growth Factor Reviews</i> , 2022, 68, 37-53.	3.2	23
1445	Distribution characteristics of SARS-CoV-2 IgM/IgG in false-positive results detected by chemiluminescent immunoassay. <i>Open Life Sciences</i> , 2022, 17, 1487-1496.	0.6	0
1446	The role of physical activity in the clinical outcomes of people diagnosed with Covid-19: A systematic review. , 2022, 1, 100007.		2
1447	Design and optimization of an IgG human ELISA assay reactive to recombinant RBD SARS-CoV-2 protein. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 7933-7948.	1.7	3
1448	Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients. <i>IScience</i> , 2022, 25, 105608.	1.9	2
1449	A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies. <i>Analytica Chimica Acta</i> , 2023, 1238, 340633.	2.6	2
1450	Optimization of purification conditions and study of antigenic properties of recombinant nucleocapsid protein of different SARS-CoV-2 strains. <i>Meditinskii Akademicheskii Zhurnal</i> , 2022, 2, 235-241.	0.2	1
1451	High prevalence of SARS-CoV-2 antibodies in pregnant women after the second wave of infections in the inner-city of Johannesburg, Gauteng Province, South Africa. <i>International Journal of Infectious Diseases</i> , 2022, 125, 241-249.	1.5	3
1452	Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study. <i>Vaccines</i> , 2022, 10, 1931.	2.1	1
1453	Development and evaluation of low-volume tests to detect and characterize antibodies to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1454	Interferon-Î» treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity. <i>Nature Communications</i> , 2022, 13, .	5.8	14
1455	Antibody tests for identification of current and past infection with SARS-CoV-2. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	32
1456	Antibody Levels Poorly Reflect on the Frequency of Memory B Cells Generated following SARS-CoV-2, Seasonal Influenza, or EBV Infection. <i>Cells</i> , 2022, 11, 3662.	1.8	13
1457	Development of ELISA-based diagnostic methods for the detection of haemorrhagic septicaemia in animals. <i>Journal of Microbiological Methods</i> , 2023, 204, 106652.	0.7	1

#	ARTICLE	IF	CITATIONS
1458	Paper-based multi-well depletion ELISA. <i>Lab on A Chip</i> , 2023, 23, 251-260.	3.1	2
1459	CD4 and IL-2 mediated NK cell responses after COVID-19 infection and mRNA vaccination in adults. <i>Immunobiology</i> , 2023, 228, 152304.	0.8	2
1461	Simultaneous detection of antibody responses to multiple SARS-CoV-2 antigens by a Western blot serological assay. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 8183-8194.	1.7	0
1462	A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1463	CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses. <i>Viruses</i> , 2022, 14, 2665.	1.5	2
1464	Mucosal delivery of nanovaccine strategy against COVID-19 and its variants. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 2897-2925.	5.7	1
1465	SARSPLEX: Multiplex Serological ELISA with a Holistic Approach. <i>Viruses</i> , 2022, 14, 2593.	1.5	0
1466	Multiplexed evaluation of immunity against SARS-CoV-2 variants using surface enhanced fluorescence from a nanostructured plasmonic chip. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	3
1467	SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF- β 2 signaling. <i>Nature Communications</i> , 2022, 13, .	5.8	18
1468	Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. <i>Nature</i> , 2023, 613, 735-742.	13.7	38
1471	Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
1472	The Role of Advanced Technologies against COVID-19: Prevention, Detection, and Treatments. <i>Current Stem Cell Research and Therapy</i> , 2023, 18, 800-828.	0.6	0
1473	Impact of prenatal COVID-19 vaccination on delivery and neonatal outcomes: Results from a New York City cohort. <i>Vaccine</i> , 2023, 41, 649-656.	1.7	8
1474	Improved Expression of SARS-CoV-2 Spike RBD Using the Insect Cell-Baculovirus System. <i>Viruses</i> , 2022, 14, 2794.	1.5	1
1475	An ultrasensitive fluorescence aptasensor for SARS-CoV-2 antigen based on hyperbranched rolling circle amplification. <i>Talanta</i> , 2023, 255, 124221.	2.9	6
1477	Bioinformatical Design and Performance Evaluation of a Nucleocapsid- and an RBD-Based Particle Enhanced Turbidimetric Immunoassay (PETIA) to Quantify the Wild Type and Variants of Concern-Derived Immunoreactivity of SARS-CoV-2. <i>Biomedicines</i> , 2023, 11, 160.	1.4	1
1478	Prevaccination Glucose Time in Range Correlates With Antibody Response to SARS-CoV-2 Vaccine in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, e474-e479.	1.8	1
1480	Prevalent and immunodominant CD8 T β cell epitopes are conserved in SARS-CoV-2 variants. <i>Cell Reports</i> , 2023, 42, 111995.	2.9	12

#	ARTICLE	IF	CITATIONS
1481	RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	1
1482	Nigeria healthcare worker SARS-CoV-2 serology study: Results from a prospective, longitudinal cohort. <i>PLOS Global Public Health</i> , 2023, 3, e0000549.	0.5	0
1483	Kinetics of Covid-19 antibodies in terms of titre and duration among healthcare workers: A longitudinal study. <i>The National Medical Journal of India</i> , 0, 35, 201-205.	0.1	0
1484	Screening and confirmation tests for SARS-CoV-2: benefits and drawbacks. <i>Beni-Suef University Journal of Basic and Applied Sciences</i> , 2023, 12, .	0.8	5
1486	Monkeypox infection elicits strong antibody and B cell response against A35R and H3L antigens. <i>IScience</i> , 2023, 26, 105957.	1.9	15
1487	Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2023, 37, e00780.	2.1	3
1490	Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. <i>Npj Vaccines</i> , 2022, 7, .	2.9	19
1491	Emerging Landscape of SARS-CoV-2 Variants and Detection Technologies. <i>Molecular Diagnosis and Therapy</i> , 2023, 27, 159-177.	1.6	6
1492	Laboratory-Based SARS-CoV-2 Receptor Binding Domain Serologic Assays Perform with Equivalent Sensitivity and Specificity to Commercial FDA-EUA Approved Tests. <i>Viruses</i> , 2023, 15, 106.	1.5	3
1493	Aptamer-Linked Photonic Crystal Assay for High-Throughput Screening of HIV and SARS-CoV-2. <i>Analytical Chemistry</i> , 0, , .	3.2	0
1494	SARS-CoV-2 infection history and antibody response to three COVID-19 mRNA vaccine doses. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	2
1495	Label-free impedimetric immunosensor for point-of-care detection of COVID-19 antibodies. <i>Microsystems and Nanoengineering</i> , 2023, 9, .	3.4	18
1496	The COVID-19 wave was already here: High seroprevalence of SARS-CoV-2 antibodies among staff and students in a Cameroon University. <i>Journal of Public Health in Africa</i> , 2023, 14, .	0.2	2
1497	Cell-Free Dot Blot: an Ultra-Low-Cost and Practical Immunoassay Platform for Detection of Anti-SARS-CoV-2 Antibodies in Human and Animal Sera. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	1
1498	Comparative Characterization of Diverse DNA Aptamers for Recognition of Spike Proteins of Multiple SARS-CoV-2 Variants. <i>Analysis & Sensing</i> , 2023, 3, .	1.1	0
1499	Chemically Amplified Multiplex Detection of SARS-CoV-2 and Influenza A and B Viruses via Paint-Programmed Lateral Flow Assays. <i>Small</i> , 2023, 19, .	5.2	3
1500	The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial. <i>International Journal of Infectious Diseases</i> , 2023, 130, 52-59.	1.5	2
1501	Gold-silver alloy hollow nanoshells-based lateral flow immunoassay for colorimetric, photothermal, and SERS tri-mode detection of SARS-CoV-2 neutralizing antibody. <i>Analytica Chimica Acta</i> , 2023, 1255, 341102.	2.6	14

#	ARTICLE	IF	CITATIONS
1502	Development of SARS-CoV-2 neutralizing antibody detection assay by using recombinant plant-produced proteins. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2023, 38, e00796.	2.1	2
1503	COVID-19: Impact, Diagnosis, Management and Phytoremediation. <i>Current Traditional Medicine</i> , 2023, 9, .	0.1	0
1504	Antibody acquisition after second and third SARS-CoV-2 vaccinations in Japanese kidney transplant patients: a prospective study. <i>Clinical and Experimental Nephrology</i> , 0, , .	0.7	0
1505	Cryo-EM reveals binding of linoleic acid to SARS-CoV-2 spike glycoprotein, suggesting an antiviral treatment strategy. <i>Acta Crystallographica Section D: Structural Biology</i> , 2023, 79, 111-121.	1.1	9
1506	Ultrasensitive lateral-flow assays via plasmonically active antibody-conjugated fluorescent nanoparticles. <i>Nature Biomedical Engineering</i> , 2023, 7, 1556-1570.	11.6	27
1507	Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers. <i>Viruses</i> , 2023, 15, 426.	1.5	3
1508	Performance estimation of two in-house ELISA assays for COVID-19 surveillance through the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulin isotypes. <i>PLoS ONE</i> , 2023, 18, e0270388.	1.1	1
1509	Autoantibodies are highly prevalent in nonâ€“SARS-CoV-2 respiratory infections and critical illness. <i>JCI Insight</i> , 2023, 8, .	2.3	9
1510	Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cellâ€“targeted therapy. <i>JCI Insight</i> , 2023, 8, .	2.3	0
1512	Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients. <i>Nature Communications</i> , 2023, 14, .	5.8	14
1513	Effect of acetic acid inactivation of SARS-CoV-2. <i>PLoS ONE</i> , 2023, 18, e0276578.	1.1	8
1514	Seroprevalence of four endemic human coronaviruses and, reactivity and neutralization capability against SARS-CoV-2 among children in the Philippines. <i>Scientific Reports</i> , 2023, 13, .	1.6	6
1515	Predictors for reactogenicity and humoral immunity to SARS-CoV-2 following infection and mRNA vaccination: A regularized, mixed-effects modelling approach. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1517	Using SARS-CoV-2 Antibody Testing in COVID-19 Research. <i>American Journal of Medicine</i> , 2023, , .	0.6	0
1518	An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	2
1519	Immunological Findings in a Group of Individuals Who Were Poor or Non-Responders to Standard Two-Dose SARS-CoV-2 Vaccines. <i>Vaccines</i> , 2023, 11, 461.	2.1	2
1520	A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. <i>Cell Reports Medicine</i> , 2023, 4, 100971.	3.3	4
1521	RBD and Spike DNA-Based Immunization in Rabbits Elicited IgG Avidity Maturation and High Neutralizing Antibody Responses against SARS-CoV-2. <i>Viruses</i> , 2023, 15, 555.	1.5	1

#	ARTICLE	IF	CITATIONS
1522	S-RBD IgG Response After Second Dose of CoronaVac; Prospective Study on Health Workers. Indonesian Journal of Clinical Pathology, 2023, 29, 74-80.	0.1	0
1523	Diagnostic TR-FRET assays for detection of antibodies in patient samples. Cell Reports Methods, 2023, 3, 100421.	1.4	0
1524	Development and validation of a rapid and easy-to-perform point-of-care lateral flow immunoassay (LFIA) for the detection of SARS-CoV-2 spike protein. Frontiers in Immunology, 0, 14, .	2.2	4
1525	Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. Frontiers in Immunology, 0, 14, .	2.2	4
1526	Capabilities of Double-Resonance LPG and SPR Methods for Hypersensitive Detection of SARS-CoV-2 Structural Proteins: A Comparative Study. Biosensors, 2023, 13, 318.	2.3	3
1527	Kinetics of dried blood spot-measured anti-SARS-CoV2 Spike IgG in mRNA-vaccinated healthcare workers. Frontiers in Microbiology, 0, 14, .	1.5	1
1528	Discriminating promiscuous from target-specific autoantibodies in COVID-19. European Journal of Immunology, 2023, 53, .	1.6	6
1529	Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants. Journal of Clinical Investigation, 2023, 133, .	3.9	4
1530	Antibody Responses to the SARS-CoV-2 Ancestral Strain and Omicron Variants in Moderna mRNA-1273 Vaccinated Active-Duty US Navy Sailors and Marines. Journal of Infectious Diseases, 2023, 228, 149-159.	1.9	3
1531	Seroconversion in COVID-19 Infection and Comparison of Antibody Responses in Symptomatic Versus Asymptomatic Individuals. Journal of Pure and Applied Microbiology, 2023, 17, 590-596.	0.3	0
1532	Comparison of vector elements and process conditions in transient and stable suspension HEK293 platforms using SARS-CoV-2 receptor binding domain as a model protein. BMC Biotechnology, 2023, 23, .	1.7	1
1533	Occupational Risk Factors for SARS-CoV-2 Seropositivity in Healthcare Workers. Journal of Occupational and Environmental Medicine, 2023, 65, 521-528.	0.9	2
1534	Active Enrichment of Nanoparticles for Ultra-Trace Point-of-Care COVID-19 Detection. Analytical Chemistry, 2023, 95, 5316-5322.	3.2	12
1535	Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination. Science Translational Medicine, 2023, 15, .	5.8	15
1536	Evaluation and deployment of isotype-specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults. Communications Medicine, 2023, 3, .	1.9	3
1538	A urine-based ELISA with recombinant non-glycosylated SARS-CoV-2 spike protein for detecting anti-SARS-CoV-2 spike antibodies. Scientific Reports, 2023, 13, .	1.6	1
1539	Plant-based biopharmaceutical engineering. , 2023, 1, 426-439.		24
1540	A pilot study: Validation of dried blood spots (DBS) to assess SARS-CoV2 IgG antibody immunoassays in underserved minority population. Heliyon, 2023, 9, e14729.	1.4	0

#	ARTICLE	IF	CITATIONS
1541	Genetically engineered pair of cells for serological testing and its application for SARS-CoV-2. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	1
1542	Robust SARS-CoV-2 T cell responses with common TCR motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells. <i>Cell Reports Medicine</i> , 2023, 4, 101017.	3.3	7
1543	A new multiplex SARS-CoV-2 antigen microarray showed correlation of IgG, IgA, and IgM antibodies from patients with COVID-19 disease severity and maintenance of relative IgA and IgM antigen binding over time. <i>PLoS ONE</i> , 2023, 18, e0283537.	1.1	3
1544	At-home sampling to meet geographical challenges for serological assessment of SARS-CoV-2 exposure in a rural region of northern Sweden, March to May 2021: a retrospective cohort study. <i>Eurosurveillance</i> , 2023, 28, .	3.9	2
1545	A RT-qPCR test targeting the conserved 5'UTR of SARS-CoV-2 overcomes major shortcomings of the first WHO-recommended RT-qPCR test. , 2023, 3, 818-846.		0
1546	Well-Defined Heparin Mimetics Can Inhibit Binding of the Trimeric Spike of SARS-CoV-2 in a Length-Dependent Manner. <i>Jacs Au</i> , 2023, 3, 1185-1195.	3.6	5
1547	Epitopes Displayed in a Cyclic Peptide Scaffold Bind SARS-CoV-2 Antibodies. <i>ChemBioChem</i> , 2023, 24, .	1.3	0
1548	Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and T cell perturbations. <i>JCI Insight</i> , 2023, 8, .	2.3	4
1549	Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. <i>Communications Biology</i> , 2023, 6, .	2.0	0
1550	Phytochemicals of <i>Withania somnifera</i> as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. <i>Microorganisms</i> , 2023, 11, 1000.	1.6	2
1551	Multiplexed on-yeast serological assay for immune escape screening of SARS-CoV-2 variants. <i>IScience</i> , 2023, 26, 106648.	1.9	1
1552	An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies. <i>AIMS Microbiology</i> , 2023, 9, 375-401.	1.0	4
1554	A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. <i>Nature Communications</i> , 2023, 14, .	5.8	21
1555	Longitudinal analysis of SARS-CoV-2 infection and vaccination in the LA-SPARTA cohort reveals increased risk of infection in vaccinated Hispanic participants. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1556	Nonlinear interdependence of the results of measuring anti-SARS-CoV-2 IgG levels using Abbott and Euroimmun test systems. <i>Journal of Clinical Virology</i> , 2023, , 105448.	1.6	1
1557	Human immune and gut microbial parameters associated with inter-individual variations in COVID-19 mRNA vaccine-induced immunity. <i>Communications Biology</i> , 2023, 6, .	2.0	8
1576	Automating Prognostics and Prevention of Errors, Conflicts, and Disruptions. <i>Springer Handbooks</i> , 2023, , 509-531.	0.3	2
1620	Rapid COVID-19 immunity screening by machine learning aided multiplexed nanoplasmonic biosensor. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
1627	Molecular testing in emerging infectious diseases. , 2024, , 175-198.		0
1628	B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. , 2024, 21, 144-158.		4
1643	Immunogenicity and Protective Efficacy of Nucleic Acid-Based Vaccines Against COVID-19: A Systematic Review. Molecular Biotechnology, 0, , .	1.3	0
1661	COVID-19 laboratory diagnosis. , 2024, , 2727-2741.		0